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Overview 
 
This thesis examines the late effects of cranial radiotherapy in adult survivors of 
childhood cancers. Part 1 is a systematic literature review which aims to extend 
previous research by summarising the neurocognitive outcomes associated with the 
specific effects of cranial radiotherapy up to 34 years after completing treatment. 
Results indicated that cranial radiotherapy has greater effects on memory, processing 
speed, and attention than intelligence and general executive functions. Younger age 
at diagnosis and higher radiotherapy dosage were also associated with increased risk 
of adverse neurocognitive outcomes in adulthood.  
 
Part 2 is an empirical paper which evaluates neurocognitive and psychosocial late 
effects of cranial radiotherapy within a specific subgroup of survivors of adolescent 
cancers. Adult survivors reported generally positive social adjustment, and IQ scores 
and levels of depression and anxiety were comparable to the normal population. 
Total radiotherapy dosage and receiving additional chemotherapy significantly 
predicted IQ. However, findings must be interpreted with caution, and the need for 
larger longitudinal studies with sufficient statistical power to fully characterise 
enduring deficits and determine factors that place survivors at greatest risk is 
discussed.  
 
Part 3 is a critical appraisal of the research process which discusses issues of project 
development and the theoretical and methodological limitations inherent in studying 
the specific effects of cranial radiotherapy. The concept of post-traumatic growth and 
its applications to the current findings are also considered. 
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Impact Statement 
 
The prognosis of childhood cancers has improved considerably in recent decades due 
to significant advances in medical technology. In particular, the inclusion of 
radiotherapy in the treatment protocols of many different cancers has been attributed 
to increased survival rates. Consequently, research into childhood cancers has 
broadened to examine the long-term outcomes associated with treatments such as 
cranial radiotherapy, referred to as late effects. 
 
The present thesis contributes to this expanding area of research by investigating 
populations that have received little attention to date. Firstly, the systematic review 
explores neurocognitive outcomes in a cohort of survivors of childhood brain 
tumours and acute lymphoblastic leukaemia treated on early radiotherapy protocols 
in the 1980s, who are now moving into middle adulthood. Although radiotherapy is 
no longer routinely given to children with acute lymphoblastic leukaemia, this 
review represents the first opportunity to examine outcomes more than ten years 
following irradiation. Adult survivors who received cranial radiotherapy in childhood 
and adolescence up to 34 years previously were identified to be at increased risk for 
neurocognitive dysfunction, especially in domains of memory, attention, and 
processing speed. Understanding the effects of childhood cancer in adulthood is 
crucial in designing healthcare services to support an ageing population of survivors, 
and suggestions of early-onset dementia also indicate the need for continued clinical 
follow-up and research in this cohort. Moreover, knowledge of likely deficits and 
risk factors revealed in this review may be important for researchers developing 
treatments that use radiation as they strive to reduce neurotoxicity whilst maintaining 
treatment effectiveness. 
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Secondly, the empirical paper also provides a unique contribution to the existing 
literature, owing to its focus on neurocognitive and psychosocial late effects in adult 
survivors of adolescent cancers treated with cranial radiotherapy. Historically, the 
adolescent population has not been differentiated from childhood cancer survivors 
despite distinct developmental, cognitive, and neurological differences. The present 
results may therefore provide the first of many incremental steps in research towards 
understanding the effects of cranial radiotherapy across the lifespan in greater detail. 
This endeavour remains important as radiotherapy treatments continue to evolve, for 
example, with the increasing use of proton beam radiotherapy. The observed lack of 
impairment within current participants may be representative of a protective effect of 
receiving cranial radiotherapy during adolescence on later functioning, however, low 
power to detect small effects within the present sample limits the ability of this thesis 
to draw these conclusions. Radiotherapy dosage and receiving additional 
chemotherapy were also found to be significant predictors of lower IQ scores. 
Although further research is needed to clarify and extend current findings, this 
information could potentially be useful for oncology departments for use in treatment 
planning with adolescents, for example, in optimising dosage, and deciding whether 
to administer concurrent treatments such as chemotherapy. In the least, it is hoped 
that the promising findings of this exploratory study will inspire further research, 
including longitudinal and prospective studies, to address the limitations often 
encountered in this complex area of research. 
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Part 1: Literature Review 
 
Neurocognitive outcomes in long-term survivors of childhood 
cancers treated with cranial radiotherapy: A systematic review 
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Abstract 
 
Aims: Although widely-reported in the paediatric literature, the effects of cranial 
radiotherapy (CRT) have only recently started to be investigated in adult survivors of 
childhood cancers. The present systematic review aimed to determine the effects of 
CRT on cognitive functioning many years after treatment, and further elucidate the 
influence of multiple risk factors on neurocognitive outcomes in this population. 
 
Methods: A systematic search of PsycINFO and Web of Science databases resulted 
in 21 published studies meeting predefined criteria, split into two groups according to 
cancer type.  
 
Results: Findings across five key domains of cognitive functioning were reviewed; 
intelligence, memory, attention, processing speed, and general executive functions. 
Three risk factors (age at diagnosis, time since treatment, CRT dose) were also 
evaluated, and anatomical correlates of CRT across included studies considered. 
 
Conclusions: Despite difficulty differentiating the effects of CRT from other 
treatments and risk factors, several studies suggested that CRT is more likely to have 
unique enduring effects on memory, attention, and processing speed than intelligence 
and general executive functions. Younger age at diagnosis and higher doses of CRT 
were associated with increased risk of adverse neurocognitive outcomes in 
adulthood, whilst few studies suggested any effect of time since diagnosis. 
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Introduction 
 
Leukaemia, central nervous system (CNS) tumours, and lymphomas are among the 
most common malignant diseases presented in childhood, accounting for 29%, 26%, 
and 11% of all childhood cancers, respectively (Siegel, Miller, & Jemal, 2017). 
Cranial radiotherapy (CRT) is a critical component of the treatment protocols for 
these cancers and has undoubtedly contributed to improved chances of survival. 
However, as survival rates have improved, attention has been turned to the long-term 
effects of treatments, including the widely-reported effects on neurocognitive 
functioning1. Despite a large literature examining the effects of CRT on the brain and 
cognition, there is ongoing controversy regarding its effects. 
 
Cranial radiotherapy (CRT) in current and historic cancer treatment protocols 
CRT uses ionising radiation to control or kill malignant cells. Although the exact 
therapeutic mechanism of CRT is still under investigation, current evidence suggests 
that radiation damages the DNA in cancerous cells, preventing reproduction and 
leading to eventual cell death (Hawley, 2013). CRT can be used as a definitive 
treatment, or adjunctively to target microscopic spread after surgery or chemotherapy 
(Snider & Mehta, 2016). Conventional external beam radiotherapy, which uses 
photons, is the most commonly used form, and total dose is usually administered in 
multiple fractions over time. The number of fractions varies depending on the type of 
cancer being treated, and is usually administered over a period of 2-7 weeks. The 
                                                 
1 The term ‘neurocognitive outcomes’ is a broad term is used by many authors referring to specific 
late effects of treatment. Other terms including ‘neurocognitive functioning’, ‘cognitive outcomes’, 
‘cognitive functioning’, ‘cognitive late effects’, ‘cognitive sequalae’ and ‘neuropsychological 
functioning’ have the same meaning and are used interchangeably throughout this review.  
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unit of radiation dose is known as a Gray (Gy), which refers to the amount of energy 
that is absorbed per unit mass. CRT is typically administered in fractions smaller 
than 2Gy, often given once daily (Tadman & Roberts, 2007; Tobias & Hochhauser, 
2009).  
 
The literature suggests that whole-brain and craniospinal radiotherapy have been 
used as methods of treating CNS cancers as early as the 1930s (Fischer & Holfelder, 
1930). CRT was first implemented to attempt to eradicate deposits found in the brain 
and spinal cord seeded from primary cerebellar tumours, which were originally 
discovered in post-mortems of untreated brain tumour patients (Paterson & Farr, 
1953). Later, in the 1960s, researchers at St Jude Children’s Research Hospital began 
to experiment with incorporating CRT into treatment protocols for acute 
lymphoblastic leukaemia (ALL) (Aur et al., 1971; George et al., 1968). CRT was 
given early in remission based on theory developed from mouse studies which 
proposed that CNS radiation may eradicate clinically undetectable leukemic cells and 
prevent the development of secondary CNS leukaemia and relapse (Aur, Simone, 
Hustu, & Verzosa, 1972). The results of these studies indicated that combination 
24Gy CRT and chemotherapy (intravenous methotrexate) was effective in preventing 
CNS relapse (Aur et al., 1972; Hustu, Aur, Verzosa, Simone, & Pinkel, 1973). 
However, reports of significant toxicity, infection, endocrine dysfunction, and 
cognitive decline started to emerge in the 1980s which led to a paradigm shift in the 
treatment of ALL; CRT was gradually replaced with contemporary therapeutic 
protocols which consist of intensified intravenous and intrathecal chemotherapeutic 
drugs and do not routinely include CRT (Pui et al., 2004; Simone, 2006).  
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Concerns over the potential long-term cognitive effects of CRT as a treatment for 
brain tumours (especially medulloblastoma) also began to arise as survival rates 
improved (Edelstein et al., 2011). CRT continues to be used to treat many brain 
tumours and current protocols prescribe maximal surgical resection, risk-based CRT 
(which usually involves targeting the entire craniospinal axis with an additional boost 
to the primary tumour site), and adjuvant chemotherapy (Gottardo & Gajjar, 2006).  
Radiotherapy regimens for paediatric brain tumours typically include higher total 
doses than for non-CNS cancers, and range between 45 and 65Gy depending on age 
and tumour factors (The Royal College of Radiologists, 2016).  Consequently, more 
recent research has focused on identifying risk factors and modifying treatments in 
an attempt to reduce risk of neurocognitive impairment where possible (e.g. Duffner, 
2004). 
 
Late effects of CRT  
The long-term impact of CRT on neurocognitive outcomes in childhood cancer 
survivors has been extensively studied, and many reviews have evaluated the 
literature to date across diagnoses. In contrast to the acute effects of CRT, which 
include fatigue, nausea, and pain, and resolve within weeks of treatment completion, 
late effects do not emerge immediately (Tadman & Roberts, 2007). Existing reviews 
suggest that children treated with CRT in ALL are at increased risk for significant 
cognitive sequelae one year or more following treatment (Duffner, 2004; Madan-
Swain & Brown, 1991) and children who receive CRT for brain tumours are even 
more vulnerable than ALL survivors (Duffner, 2004; Roman & Sperduto, 1995). 
Specifically, cognitive deficits have been suggested across domains of intellectual 
functioning, academic achievement, memory, attention, and processing speed for 
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medulloblastoma survivors (Palmer, Reddick, & Gajjar, 2007) and samples of mixed 
CNS tumours (Mulhern, Hancock, Fairclough, & Kun, 1992; Mulhern, Merchant, 
Gajjar, Reddick, & Kun, 2004). More rigorous reviews in paediatric brain tumour 
survivors employing meta-analytical (Robinson, Fraley, Pearson, Kuttesch, & 
Compas, 2013) and systematic (Wolfe, Madan-Swain, & Kana, 2012) approaches 
found significant deficits in overall cognitive ability and attention, working memory, 
processing speed, and general executive functions for survivors treated with CRT. 
 
Despite the relative abundance of reviews which conclude adverse neurocognitive 
outcomes in survivors of brain tumours and ALL resulting from CRT, Armstrong, 
Gyato, Awadulla, Lustig, and Tochner (2004) describe the damaging effects of CRT 
as “more elusive and less robust than has been generally appreciated” (p.82). 
Namely, there are a great number of confounding factors in this area of research 
which make interpretation of neurocognitive data difficult and question the validity 
of conclusions about the specific effects of CRT. Many risk factors for cognitive 
deterioration following CRT have been identified, including: tumour type, size, 
location, use of chemotherapy, hydrocephalus requiring shunt, and time since 
treatment, with younger age at diagnosis, and higher CRT dose being possibly the 
most well-documented (Armstrong et al., 2004; Duffner, 2010; Edelstein et al., 2011; 
Hoppe-Hirsch et al., 1990; Mulhern et al., 2004; Mulhern et al., 2005; Robinson et 
al., 2013; Ullrich & Embry, 2012). Although less consistently investigated, other risk 
factors such as female gender, treatment-related complications, and relapse have also 
been suggested to predict cognitive impairment (Ellenberg et al., 2009; Krull, 
Brinkman, et al., 2013; Schuitema et al., 2015). 
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Armstrong et al. (2004) further suggest that the failure of most studies to isolate the 
effects of CRT is due to feasibility rather than poor study design. Indeed, although 
the present review seeks to examine the specific effects of CRT on neurocognitive 
outcomes, it is impossible to account for the many patient and treatment-related risk 
factors and their complex interactions entirely. This review will attempt to address 
the influence of several widely-reported risk factors on neurocognitive outcomes 
following CRT treatment including cancer type, dosage, age at diagnosis, and time 
since diagnosis. 
 
Neurocognitive outcomes in adulthood 
Whilst prior literature has provided valuable information concerning the effects of 
CRT in the few years following treatment, it has been limited so far by the age of the 
participants involved and the follow-up intervals used. Given that CRT was only 
more widely used as treatment for cancer from the 1980s onwards, research to date 
has tended to examine neurocognitive outcomes in survivors after a maximum of ten 
years, with the majority of studies examining childhood cancer survivors fewer than 
five years post-treatment. Accordingly, little is known about neurocognitive sequelae 
of CRT for childhood cancers in adulthood. Since brain development continues well 
into adulthood (Giedd et al., 1996; Huttenlocher, 1979), it is logical to assume that 
the extent of impairment may change as survivors mature.  
 
Previous studies that evaluated survivors up to ten years post-treatment have 
suggested that cognitive decline is progressive over time (e.g. Duffner, 2004; Hoppe-
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Hirsch et al., 1990), or decline is steep in the first few years post-treatment and is 
then more gradual (Spiegler, Bouffet, Greenberg, Rutka, & Mabbott, 2004). 
Modelling used to estimate the rate of change in IQ in medulloblastoma patients 
treated with CRT has produced estimates that vary from -2.05 to -4.30 points per 
year (Palmer et al., 2001; Palmer et al., 2003; Ris, Packer, Goldwein, Jones-Wallace, 
& Boyett, 2001; Walter et al., 1999). However, it is not possible to predict decline 
across the lifespan from these studies, highlighting the need for research over longer 
periods.  
 
Recent studies examining childhood brain tumour and ALL survivors treated with 
CRT 20 years or more after treatment suggest that cognitive decline continues 
(Harila, Winqvist, Lanning, Bloigu, & Harila-Saari, 2009; Krull, Zhang, et al., 2013). 
It has also been suggested that irradiated survivors are at increased risk for early-
onset dementias as their cognitive profiles have been shown to be consistent with 
accelerated ageing (Armstrong et al., 2013; Daams et al., 2012; Schuitema et al., 
2013). However, it is important to distinguish whether these declines represent true 
deficits in functioning at this stage post-treatment. Longitudinal studies that identify 
CRT-induced declines in IQ have also found that abilities may initially remain within 
normal limits if individuals with high premorbid IQ (and greater associated cognitive 
reserves) are included (e.g. Edelstein et al., 2011; Krull, Zhang et al., 2013). It is also 
possible that survivors treated with CRT may experience poorer neurocognitive 
outcomes than those treated with other modalities, but remain within normal limits.   
 
17 
 
Rationale and aims of the review 
To date, no review has investigated the effects of CRT specifically on adult survivors 
of childhood cancers. Although CRT is no longer routinely given to children with 
ALL, studies of these survivors have important implications for the large population 
of long-term survivors treated under previous protocols. Moreover, a review in this 
area may help to further current knowledge of CRT as it is applied in current 
treatment protocols. Given the suggestion that some neurocognitive functions, such 
as IQ, may be subject to CRT-induced decline but remain within normal limits, the 
effects of CRT are mostly evaluated with respect to other treatment modalities, but 
also inspected with regards to impairment2 in this review. 
 
The present review aims to answer the following questions: 
1. What are the cognitive late effects of CRT in adult survivors of childhood 
cancers across the major domains of cognitive functioning? 
2. Is there an effect of cancer type i.e. does CRT have different effects on CNS 
cancers compared to non-CNS cancers? 
3. Are outcomes also related to: a) age at diagnosis, b) time since treatment, c) 
CRT dosage?  
4. What are the effects of CRT on brain structures and activity? 
 
                                                 
2 The terms ‘impairment’ and ‘impaired’ will be used throughout the review to indicate that scores fell 
below the average range when compared to healthy population norms. This differentiation is made as 
it is possible that studies may demonstrate a specific adverse effect of CRT, such that those receiving 
CRT show poorer scores than those treated with chemotherapy and/or surgery, whilst remaining 
within normal limits.  
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Method 
 
Inclusion and exclusion criteria 
Inclusion criteria were established according to the review objectives and using the 
population, intervention, comparator, and outcome tool (Stone, 2002), as follows: 
1. Publications: 
a. Published in a peer-reviewed journal between 1900 and 2018 
b. Available in English 
2. Population: 
a. Studies of long-term survivors of childhood cancers, defined as those 
who were diagnosed and treated for cancer before the age of 18 years 
old, were at least 16 years old at the time of assessment, and 
completed treatment at least five years prior to participation 
3. Design: 
a. Case-control, cross-sectional, and longitudinal designs 
4. Interventions and Comparator/Control 
a. Include a cohort of cancer survivors who received CRT 
b. Involve a comparative group or include analysis partialling out effects 
of CRT 
5. Outcome 
a. Include one or more measures of cognitive functioning in adulthood 
No date limitation was imposed, to include cohorts of participants treated on 
previous treatment protocols. Inclusion criteria explicitly allowed for different cancer 
diagnoses where CRT was included in the treatment protocol, to allow for 
comparison within the current review. Records were excluded if they were reviews, 
meta-analyses, or commentaries. Due to the specific nature of the review question, 
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studies that included a mixed population of children and young adults were excluded 
unless children and adult outcome data was analysed separately. Animal studies were 
also excluded. 
 
Search strategy 
Systematic searches were conducted using PsycINFO (1806 to January 2018), and 
Web of Science databases (all databases; 1900 to January 2018).  The following 
combination of keywords was used across all databases: (radiotherapy or radiation) 
AND (cancer) AND (cognitive or cognitive function* or neuropsych* or attention or 
executive or memory or language or motor or coordination) AND (long-term or 
dysfunction* or deficit* or impairment* or sequelae* or outcome* or effect* or 
result* or problem* or challenge* or impact* or late effect*) AND (crani* or 
brain*) AND (survivor* or young adult* or aya or adult) AND (adolescen* or 
teenage* or pediatric or paediatric or child* or childhood). Initial searches yielded a 
total of 789 results. Duplicates were removed, leaving a total of 691 records, and the 
remaining articles underwent a stepwise search strategy conducted at three levels, 
depicted in Figure 1. First, titles were screened to exclude review articles and studies 
clearly unrelated to review objectives. The abstracts of the remaining 445 papers 
were then reviewed and excluded according to the afore-mentioned criteria. Where it 
was not possible to determine inclusion from abstracts alone, studies progressed to 
the third stage of selection for more detailed review. In this stage, 90 records were 
reviewed in full against inclusion and exclusion criteria. The majority of studies were 
excluded due to irrelevant context, or because participants were younger than 16 
years of age at the time of assessment, and/or because studies did not include 
participant subgroups or statistical analysis specific to the effects of CRT over other 
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types of treatments. Reference lists of these studies were also manually searched, and 
ten additional relevant publications were identified which were also read in full. A 
total of 21 studies met criteria for inclusion in the review (summarised in Tables 3 
and 4).  
 
 
Figure 1. Flow chart of search results and screening process 
 
 
Data extraction 
The following information was abstracted for each study a) demographic information 
including mean age at diagnosis; mean age at evaluation; mean time since treatment 
b) study information including: year of publication; study location; design; whether it 
was part of a larger study; sample size; c) type of cancer studied, d) treatment 
Records identified through 
database searches (n = 789) 
Total after duplicates removed  
(n = 691) 
Records identified for abstract 
review (n = 445) 
Records excluded at title stage  
(n = 246) 
Full-text records evaluated against 
inclusion/exclusion criteria (n = 90) 
Records included (n = 21) 
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information including combination of treatments received and CRT dosage, d) 
outcomes information including: cognitive domains assessed; cognitive measures 
used; other outcome measures; statistical analysis used to differentiate effects of 
CRT, and e) findings relevant to the effects of CRT. 
 
Categorisation of studies 
Cancer type. Given that records were not selected based on specific types of 
cancer, studies were separated according to whether cancer originated in the central 
nervous system; eight studies focused on cancers originating in the central nervous 
system (CNS) summarised in Table 3, and thirteen studies focused on cancers not 
originating in the central nervous system (non-CNS), for which CRT is still a 
primary treatment, summarised in Table 4.  
 
Six CNS studies contained mixed samples made up of participants with various brain 
tumours, commonly including medulloblastoma and astrocytoma. The remaining two 
CNS studies focused on pure samples of retinoblastoma and medulloblastoma 
patients, respectively (Brinkman et al., 2015; Maddrey et al., 2005). The majority of 
non-CNS studies comprised pure samples of acute lymphoblastic leukaemia (ALL) 
survivors. Of the remaining three, two contained mixed samples of ALL and other 
non-CNS cancers (Kadan-Lottick et al., 2010; Winqvist, Vainionpää, Kokkonen, & 
Lanning, 2001) and the third focused on a pure sample of participants who 
underwent treatment for non-Hodgkin lymphoma (Ehrhardt et al., 2018).  
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Table 1.  
Methods of Differentiating Specific Effects of CRT across Studies 
Study 
 
CNS Studies 
Ailion et al., 2016 No-CRT vs CRT 
Armstrong et al., 2010 No-CRT vs different dosages of CRT 
Brinkman et al., 2015 All participants - regression 
Ellenberg et al., 2009 No-CRT vs different dosages of CRT 
Jayakar et al., 2015 No-CRT vs CRT 
King et al., 2017 No-CRT vs CRT 
Maddrey et al., 2005 All participants - regression 
Reimers et al., 2013 All participants - regression 
Non-CNS Studies 
Armstrong et al., 2013 Dosage comparison 
Daams et al., 2012 No-CRT vs CRT 
Edelmann et al., 2014 No-CRT vs CRT 
Ehrhardt et al., 2018 All participants - regression 
Harila et al., 2009 No-CRT vs different dosages of CRT 
Kadan-Lottick et al., 2010 No-CRT vs different dosages of CRT 
Krull, Brinkman, et al., 2013 All participants - regression 
Krull, Zhang, et al., 2013 No-CRT vs different dosages of CRT 
Krull et al., 2014 Dosage comparison 
Link et al., 2006 All participants - regression 
Schuitema et al., 2013 No-CRT vs CRT 
Schuitema et al., 2015 All participants - regression 
Winqvist et al., 2001 No-CRT vs CRT 
 
 
CRT. All studies included a subgroup of participants who had received CRT. 
However, according to the treatment protocols for many different types of cancer, 
most participants across all studies also received further treatment in addition to  
CRT, such as chemotherapy and/or surgery. Given that this review aims to evaluate 
the specific effects of CRT, only studies that included a method for differentiating 
the effects of CRT were included. The 21 studies were categorised accordingly (see 
Table 1); seven studies compared a CRT group to a no-CRT group, five studies 
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compared a no-CRT group to multiple groups who received different dosages of 
CRT, two studies compared two groups who received different dosages of CRT, and 
a further seven studies evaluated the association between CRT dose and impairment 
across all participants using regression analyses. 
 
Characteristics of studies 
Design. Across all CNS and non-CNS studies, the majority (90%) had a 
cross-sectional design, evaluating participants at a single interval. Only two 
longitudinal studies evaluated changes in survivors’ cognitive abilities from active 
treatment to remission in adulthood (Harila et al., 2009; Krull, Zhang, et al., 2013); 
one of these studies also included further cross-sectional analysis (comparison to 
healthy controls) (Harila et al., 2009). The 21 studies were conducted in five 
different countries; the United States (n=14), the Netherlands (n=3), Finland (n=2), 
Sweden (n=1), and Denmark (n=1). 
 
Participants. A total of nine studies recruited participants from existing 
cohort studies in the US; in six studies, participants were recruited from a cohort of 
over 1400 participants in the larger St. Jude Lifetime Cohort (SJLIFE) study 
(Brinkman et al., 2015; Edelmann et al., 2014; Ehrhardt et al., 2018; Krull, 
Brinkman, et al., 2013; Krull, Zhang, et al., 2013; Krull et al., 2014), which evaluates 
medical and psychosocial late effects in adult survivors of childhood cancer at St 
Jude Children’s Research Hospital (Hudson et al., 2011). All participants in this 
cohort study were at least 18 years of age and ten years or more from diagnosis. 
Exclusion criteria included history of developmental disorder, neurologic event 
unrelated to cancer, and relapse. A further three studies (Armstrong et al., 2010; 
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Ellenberg et al., 2009; Kadan-Lottick et al., 2010) recruited eligible participants from 
the Childhood Cancer Survivor Study (CCSS), which is a large retrospective cohort 
study of children and adolescents with longitudinal follow up across 26 institutions 
in the US and Canada (Robison et al., 2002). All participants in this cohort study 
were diagnosed in childhood and had a survival rate of at least five years. 
 
Sample size of treatment groups (excluding healthy controls) ranged from 16 to over 
4000, but two thirds of the studies (67%) included between 25 and 135 participants 
who had received cancer treatment. Fourteen studies included additional healthy 
control groups and ten studies evaluated participants against population norms; three 
studies utilised both healthy controls and population norms (Armstrong et al., 2010; 
Edelmann et al., 2014; Ehrhardt et al., 2018). Most studies (90%) reported mean age 
at diagnosis, which ranged from 1.9 to 10.4. All studies reported mean age at 
evaluation, which was 28.8 years old on average, and ranged from 16.0 to 38.4. All 
except two studies reported mean time since treatment ended, which was 22 years on 
average, with a range of 9.7 to 33.5 years across CNS and non-CNS studies. 
 
Measures. The neuropsychological tests used to assess cognitive functioning 
are detailed in Table 2. Seven studies (2 CNS, 5 non-CNS) also utilised structural 
neuroimaging including: structural magnetic resonance imaging (MRI) [n=5], 
functional magnetic resonance imaging (fMRI) [n=1], volumetric/atrophy analysis 
[n=3], diffusion-tensor imaging (DTI) [n=3], magnetoencephalography (MEG) 
[n=1], and fluorodeoxyglucose-positron emission tomography (F-FDG PET)[n=1], 
alongside measures of cognitive functioning. 
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Table 2.  
Neurocognitive Measures used in Included Studies 
Study Intelligence Memory Attention Processing Speed General Executive Functions 
CNS Studies 
Ailion et al., 2016 
   
SDMT 
 
Armstrong et al., 2010 
 
CCSS-NCQ CCSS-NCQ 
 
CCSS-NCQ 
Brinkman et al., 2015 WASI CVLT-II CPT-II, TMTa,  
WAIS-III DSf 
WAIS-III CD TMTb, COWAT, WAIS-III 
DSf, BRIEF 
Ellenberg et al., 2009 
 
CCSS-NCQ CCSS-NCQ 
 
CCSS-NCQ 
Jayakar et al., 2015 WASI CVLT-II 
   
King et al., 2017 WASI ACT WMS DSf OSDMT 
 
Maddrey et al., 2005 WAIS-III (2 subtests) CVLT, Rey-O CPT, TMTa 
 
TMTb, COWAT, WCST 
Reimers et al., 2013 WAIS-R 
    
Non-CNS Studies 
Armstrong et al., 2013 WASI (data NR) WMS-IV, BCSE 
   
Daams et al., 2012 
 
ANT ANT ANT ANT 
Edelmann et al., 2014 WASI CVLT-II, WAIS-III 
DSf, TML-II 
TMTa, CPT-II GPT,  
PSI from WAIS-III 
TMTb, COWAT, WAIS-III 
DSb 
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Ehrhardt et al., 2018 WASI CVLT-II, WAIS-III 
DSf, TML-II 
TMTa, CPT-II GPT,  
PSI from WAIS-III 
TMTb, COWAT, WAIS-III 
DSb, BRIEF 
Harila et al., 2009 WAIS (7 subtests) WMS, HIMT, VLT, 
BVRT 
TMTa, TMTb, SCWT 
  
Kadan-Lottick et al., 2010 
 
CCSS-NCQ CCSS-NCQ 
 
CCSS-NCQ 
Krull, Brinkman, et al., 2013 WASI CVLT-II CPT-II, WAIS-III PSI from WAIS-III WAIS-III, Other test NR 
Krull, Zhang, et al., 2013 WASI 
    
Krull et al., 2014 WASI CVLT-II CPT-II, WAIS-III, 
Other test NR 
CPT-II, WAIS-III, Other 
test NR 
WAIS-III, Other test NR 
Link et al., 2006 WAIS-R (3 subtests), 
SRB Vocab 
CMVMT APT k-test APT RT-2 AM, APT RT-Inhibition 
Schuitema et al., 2013 WAIS-R (4 subtests) ANT ANT ANT 
 
Schuitema et al., 2015 WAIS-III (4 subtests) ANT ANT ANT ANT 
Winqvist et al., 2001 WAIS (6 subtests) WMS DSf DSb, BVRT 
 
TMTa, TMTb, SCWT, 
PPT, RRT, WAIS-III CD 
TMTa, TMTb, BWT, SCWT 
*ACT, Auditory Consonant Trigram 36s trial; AM, Austin Maze Test; ANT, Amsterdam Neuropsychological Tasks; APT RT-2, Automated Psychological Test System Reaction Time Test; 
APT RT-Inhibition, Automated Psychology Test Inhibition Test; BCSE, Brief Cognitive Status Exam; BRIEF, Behaviour Rating Inventory of Executive Function; BVRT, Benton Visual 
Retention Test; BWT, Bourdon-Wiersma Test; CCSS-NCQ, Childhood Cancer Survivor Study Neurocognitive Questionnare; COWAT, Controlled Oral Word Association Test; CMVMT, 
Cronholm-Molander Verbal Memory Test; CPT, Conners' Continuous Performance Test; CPT-II, Conners' Continuous Performance Test-II; CVLT, California Verbal Learning Test; CVLT-II, 
California Verbal Learning Test-II;  HIMT, Homogeneous Inference Memory Test;  OSDMT, Oral Symbol Digit Modality Test; PSI, Processing Speed Index; Rey-O, Rey-Osterrieth Complex 
Figure Test; RTT, Reaction Time Test; SCWT, Stroop Colour Word Test; SDMT, Symbol Digit Modality Test; SRB Vocab, SRB 1 Vocabulary from the DS Battery; TMTa, Trail-making Test 
Part A; TMTb, Trail-making Test Part B; TML-II, Test of Memory and Learning-I; VLT, Verbal Learning Task; WAIS, Wechsler Adult Intelligence Scale; WAIS-III, Wechlser Adult 
Intelligence Scale-III; WAIS-III CD, Coding subtests; WAIS-III DSb, Digit Span backwards subtests; WAIS-III DSf, Digit Span forward subtests; WAIS-R, Wechsler Adult Intelligence Scale-
Revised; WASI, Wechsler Abbreviated Scale of Intelligence; WCST, Wisconsin Card Sorting Test; WMS, Wechsler Memory Scale; WMS-IV, Wechsler Memory Scale-IV; WMS DSf, Digit 
Span forwards subtests 
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Results 
 
Information extracted from the studies in the present review will be synthesised and 
structured in the order of the research questions. It will first focus on the 
neurocognitive late effects of CRT, according to five domains across the 21 studies, 
separated for CNS and non-CNS cancer survivors (summarised in Table 5). Three 
risk factors (age at diagnosis, time since treatment, CRT dose) will also be evaluated 
(summarised in Table 6), and anatomical correlates of CRT considered. 
 
Intelligence  
The most widely used measures of intellectual functioning are the Wechsler scales, 
which purport to measure “the global capacity of a person to act purposefully, to 
think rationally, and to deal effectively with his environment” (Wechsler, 1958, p.7). 
Fifteen studies (5 CNS, 10 non-CNS) investigated the effects of CRT on IQ. The 
most frequently used measure was the Wechsler Abbreviated Scale of Intelligence 
(WASI), which is a shortened version of the full battery, yielding three index scores; 
full-scale IQ, verbal comprehension, and perceptual reasoning. 
 
CNS studies 
Of the five studies that examined IQ in CNS tumour survivors, two identified 
specific effects of CRT leading to impairment; CRT survivors were found to have 
significantly lower full scale IQ (in the low range; mean IQ=75-78.8) compared to 
chemotherapy survivors and controls (Maddrey et al., 2005; Reimers et al., 2003), 
with one suggesting stronger effects of CRT on perceptual reasoning over verbal 
comprehension (Maddrey et al., 2005; Reimers et al., 2003). A further two studies 
found a specific effect of CRT such that those who received CRT achieved lower IQ 
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scores than those treated with other modalities and controls, but IQ remained within 
the average range (Jayakar, King, Morris, & Na, 2015; King, Ailion, Fox, & 
Hufstetler, 2017). The remaining study did not find any association between CRT 
and IQ (Brinkman et al., 2015).  
 
Non-CNS studies 
Only one non-CNS study suggested that CRT may impair aspects of intellectual 
functioning; Krull et al., (2014) found that scores on a vocabulary subtest in a small 
sample of 38 ALL survivors were significantly lower than population norms for even 
low doses of CRT. 
 
Seven studies did not suggest any effect of CRT on intelligence above other 
treatments. Five of these studies compared an overall non-CNS survivors group 
(CRT and other treatments included) to controls or population norms and found that 
survivors had lower IQs than controls, but were still within the average range 
(Ehrhardt et al., 2018; Krull, Zhang, et al., 2013; Link et al., 2006; Schuitema et al., 
2015; Winqvist et al., 2001). Three of these studies included further analysis yet 
failed to detect independent effects of CRT on IQ for ALL, non-Hodgkin’s 
lymphoma, and mixed non-CNS tumours. When subgroups of ALL survivors who 
received CRT and chemotherapy, chemotherapy only, and controls were compared, 
IQ was significantly poorer in the CRT group than controls but not statistically 
different to the chemotherapy group, suggesting no distinct effect of CRT (Edelmann 
et al., 2014; Schuitema et al., 2013). 
 
A further two studies found that CRT survivors had significantly poorer scores than 
controls and other treatment groups but scores remained within the average range 
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(Harila et al., 2009; Krull, Brinkman et al., 2013). Of note, Harila et al.’s (2009) 
longitudinal data revealed decline in verbal comprehension index points for both 
CRT (7 points) and no-CRT (8 points) subgroups, and perceptual reasoning decline 
only for the CRT group (12 points) from first assessment to five years post-
treatment. Moreover, verbal comprehension and perceptual reasoning scores in the 
CRT subgroup continued to decline from five to 20 years post-treatment, whilst the 
no-CRT group scores did not. However, in a similar longitudinal study, Krull, Zhang 
et al. (2013) reported that, despite their overall finding that survivors treated with 
CRT experienced initial declines in perceptual reasoning followed by later declines 
in verbal comprehension, this was not the case for 48% of survivors who did not 
demonstrate any significant decline in verbal comprehension over time. 
 
Conclusions 
Only studies of childhood CNS cancers which differentiated the effects of CRT 
suggested intellectual impairment up to 34 years later, particularly in perceptual 
reasoning. Most other studies indicated that, even if a differential effect of CRT was 
found, IQ was not impaired relative to controls or population norms. However 
longitudinal data suggest that these survivors may still have experienced significant 
declines above those of survivors who did not receive CRT. It is also important to 
note that most studies used estimates of IQ based on limited subtests, and only one 
study (Reimers et al., 2003) calculated an estimate of full scale IQ based on subtests 
also assessing working memory and processing speed. Given that these cognitive 
functions are proposed to be significantly affected by CRT, it is possible that all 
other included studies overestimated full scale IQ. Further research using full version 
of the Wechsler scales is required to account for this interaction, and further 
elucidate the effects of CRT on overall intellectual functioning.
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Table 3.  
Overview of CNS Cancer Studies 
Study Design, 
Country 
Cancer type Comparative 
groups 
Treatment 
sample 
(percentage of 
sample receiving 
CRT) 
Dosage 
(SD) 
Mean/ 
median 
age at 
diagnosis 
(SD) 
Range 
Mean/ 
median 
age at 
evaluation  
(SD) 
Range 
Mean/ 
median 
time since 
treatment 
(SD) 
Range 
Domains 
assessed 
 
Other 
measures 
Relevant findings 
Ailion et 
al., 2016 
Cross-
sectional  
US 
13 
medulloblastoma 
10 astrocytoma 
1 ependymoma 
1 pineoblastoma 
25 matched 
healthy 
controls 
14 CRT + 
chemotherapy 
10 surgery only 
1 chemotherapy 
only 
25 total (56%) 
NR 9.3 
(5.1) 
1-19 
23.7 
 (5.1) 
18-35 
15.0  
(5.0) 
NR 
Processing 
speed 
 
MRI, atrophy, 
lesion size, 
social status 
• Adult survivors of 
paediatric cerebellar tumours 
diagnosed at a young age and 
treated with CRT displayed 
the highest amount of 
cerebellar atrophy  
• Greater cerebellar atrophy 
was associated with poorer 
oral and written processing 
speed for individuals with 
smaller lesion sizes 
Armstrong 
et al., 2010 
Cross-
sectional 
US 
523 astrocytoma 
169 
medulloblastoma 
126 other CNS 
tumour 
Sibling group  
Population 
norms  
CCSS 
333 CRT + 
surgery 
164 CRT + 
surgery + 
chemotherapy 
271 surgery only 
50 other 
818 total (63.6%) 
Radiation 
dosimetry 
method used  
Ranges: 
0-30Gy 
30-50Gy 
>50Gy 
NR 
NR 
0-20 
31.3  
(7.0) 
18.3-51.8 
>5 years 
NR 
NR 
Memory, 
attention, 
executive 
functioning 
 
Health-related 
Quality of Life  
• CRT to the temporal region 
(but not other regions) was 
significant associated with 
memory problems and poor 
task efficiency. 
• Dose-response effect of 
CRT dose in memory 
problems and poor task 
efficiency 
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Brinkman 
et al., 2015 
Cross-
sectional 
US 
Retinoblastoma  Population 
norms 
SJLIFE 
6 CRT only 
26 surgery only 
6 CRT + surgery 
3 CRT + 
chemotherapy 
13 surgery + 
chemotherapy 
15 CRT + 
chemotherapy + 
surgery 
69 total (43%) 
Mean brain 
dose 26.3Gy 
(18.8) 
 
1.9  
(1.7) 
0.0-7.1 
32.5  
(6.7) 
20.5 - 46.2 
30.6  
(6.6)  
17.2-45.5 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
Questionnaire 
data including 
demographics 
and history 
• Survivors diagnosed at <1 
year of age performed 
significantly better on 
measures of verbal memory, 
verbal learning, and verbal 
reasoning abilities  
• Increased whole brain 
radiation exposure was 
associated with poorer 
performance on verbal 
memory tasks, after adjusting 
for age at diagnosis 
Ellenberg et 
al., 2009 
Cross-
sectional 
US 
495 astrocytoma 
172 
medulloblastoma 
135 other CNS 
tumour 
5870 
survivors of 
non-CNS 
cancers 
382 sibling 
controls 
CCSS 
13 CRT only 
225 surgery only 
3 CRT + 
chemotherapy 
12 chemotherapy 
+ surgery 
344 CRT + 
surgery 
150 CRT + 
chemotherapy + 
surgery  
802 total (63.6%) 
62% 
irradiated 
CNS 
survivors 
received 
>40 Gy  
 
92% 
irradiated 
non-CNS 
survivors 
received 
<40Gy  
NR 
NR 
0 - 20 
31.5  
(7.1) 
17.4 - 51.8 
NR 
NR 
16.1-34.6 
Memory, 
attention, 
executive 
functioning 
• CNS malignancy survivors 
reported significantly greater 
neurocognitive dysfunction 
than the sibling cohort or 
non-CNS malignancy 
survivors  
• For CNS survivors, CRT 
was correlated with greater 
impairment on Task 
Efficiency and Memory 
• Dose-response effect of 
CRT  
Jayakar et 
al., 2015 
Cross-
sectional 
US 
10 astrocytoma 
9 medulloblastoma 
5 
craniopharyngioma 
3 ganglioglioma 
8 other CNS 
tumours 
59 matched 
healthy 
controls 
CRT group: (5 
CRT only 
11 CRT + 
chemotherapy) 
No-CRT group: 
(1 chemotherapy, 
18 treatments NR) 
35 total (46%) 
Mean dose 
in CRT 
group 54.1 
Gy (1.35) 
Range 50-
55.8Gy 
8.2 
(5.3) 
1-17 
24.1  
(4.9) 
17-36 
15.4  
(5.3) 
5-24 
Intelligence, 
memory 
 
MRI, Brain 
volume, 
hippocampus 
volume, 
putamen 
volume 
• The volumes for subcortical 
structures (hippocampus and 
putamen) of the no-CRT 
group were similar to those of 
controls and smaller for the 
CRT group.  
• Whole brain volumes of 
CRT and no-CRT groups are 
similar, but significantly 
smaller than controls 
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King et al., 
2017 
Cross-
sectional 
US 
19 astrocytoma 
18 embryonal 
tumour 
4 craniopharyngioma 
3 ganglioglioma 
3 ependymoma 
3 glioma 
8 other tumour 
57 matched 
healthy 
controls 
10 CRT only 
1 chemotherapy 
only 
17 CRT + 
chemotherapy 
29 No CRT 
(treatment NR) 
57 total (47%) 
NR - coded 
as 
dichotomous 
variable (RT 
vs no RT) 
7.8  
(4.6) 
1-17 
24.2  
(4.9) 
18-35 
16.5  
(6.6) 
5-30 
Intelligence, 
memory, 
attention, 
processing 
speed 
 
Medical 
records, SES  
• Within CRT survivors, a 
greater number of individuals 
exhibited impairment across 
all measures relative to the 
no-CRT group and controls 
• Younger age at diagnosis 
and CRT resulted in lower 
processing speed  
Maddrey et 
al., 2005 
Cross-
sectional 
US 
16 
medulloblastoma 
Population 
norms 
7 CRT only 
9 CRT + 
chemotherapy 
8 and 10 
participants had 
surgery and VP 
shunt placements, 
respectively  
16 total (100%) 
BED used - 
Across RT 
group mean 
dose 37.9Gy 
with 15.5 
Gy posterior 
fossa boost 
(mean total 
dose 53.4 
Gy) 
7.3  
(4.5) 
NR 
21.9  
(3.6) 
NR 
14.6  
(3.5) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning 
 
Quality of life, 
psychological 
distress  
• Younger age at diagnosis 
was associated with greater 
executive function 
impairment, and greater time 
since diagnosis were related 
to deficits in verbal memory. 
• No significant associations 
between current age, CRT 
dose, use of chemotherapy, 
VP shunt placement, and 
level of neuropsychological 
impairment. 
Reimers et 
al., 2003 
Cross-
sectional 
Denmark 
24 
medulloblastoma 
71 astrocytoma 
8 ependymoma 
9 glioma 
4 
craniopharyngioma 
8 germ cell  
9 other CNS 
tumour 
Population 
norms 
55 surgery only 
4 CRT only 
44 CRT + surgery 
2 chemotherapy + 
surgery 
28 CRT + 
chemotherapy + 
surgery 
133 total (57%) 
28 whole 
brain, mean 
35Gy plus 
19Gy boost 
to tumour 
19 whole 
brain only, 
mean 54Gy  
29 focal, 
mean 51Gy  
8.2  
(3.8) 
0-14.9 
21.1  
(7.9) 
NR 
13.3  
(7.3) 
2-27.9 
Intelligence 
 
Rappaport 
Disability 
Rating Scale 
Form 
• Effects of CRT was 
stronger on performance IQ 
than verbal IQ; higher 
performance than verbal IQ 
was only observed in the non-
irradiated group 
• CRT was the biggest risk 
factor for impaired cognitive 
outcome. Younger age at 
diagnosis, tumour site in the 
cerebral hemisphere and 
hydrocephalus were also risk 
factors. Results were not 
significantly affected by 
whole brain vs focal CRT  
*BED, biologically effective dose; CCSS, Childhood Cancer Survivor Study; DTI, diffusion tensor imaging; NR, not recorded; MRI, magnetic resonance imaging; SES, socioeconomic status; 
SJLIFE, St Jude Lifetime Cohort Study; 
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Table 4.  
Overview of Non-CNS Cancer Studies 
Study Design, 
Country 
Cancer type Comparative 
groups 
Treatment 
sample 
(percentage of 
sample 
receiving CRT) 
Dosage 
(SD) 
Mean/ 
median 
age at 
diagnosis 
(SD) 
Range 
Mean/ 
median age 
at 
evaluation  
(SD) 
Range 
Mean/ 
median 
time since 
treatment 
(SD) 
Range 
Domains 
assessed 
 
Other 
measures 
Relevant findings 
Armstrong 
et al., 2013 
Cross-
sectional 
US 
ALL Population 
norms 
265 CRT + 
chemotherapy 
265 total 
(100%) 
127: 18Gy 
138: 24Gy 
6.9  
(4.0) 
NR 
37.1  
(6.6) 
NR 
29.1  
(6.6) 
NR 
Intelligence, 
memory 
 
MRI with 
DTI, medical 
assessment, 
questionnaire 
data  
• Survivors who received 18 Gy 
CRT had no statistically 
significant impairment in 
immediate or delayed memory. 
Those who received 24 Gy 
showed twice the rate of 
impairment. 
• Memory impairment was 
related to brain imaging 
Daams et 
al., 2012 
Cross-
sectional 
Netherlands 
ALL 35 healthy 
controls 
18 
chemotherapy 
only  
14 CRT + 
chemotherapy 
32 total (43.7%) 
25Gy 5.7  
(3.4) 
NR 
31.0  
(4.3) 
NR 
25.3  
(2.5) 
NR 
Memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
MEG 
• The chemotherapy + CRT 
group performed worse than 
controls on measures of 
cognitive flexibility, attentional 
fluctuations during sustained 
attention, visuomotor accuracy 
and sequential visuospatial 
working memory 
• Findings suggest that the 
irradiated brain might be ageing 
faster and could be at risk for 
early-onset dementia. The 
chemotherapy group showed no 
signs of early ageing. 
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Edelmann et 
al., 2014 
Cross-
sectional 
US 
ALL Population 
norms 
23 healthy 
controls 
SJLIFE 
36 
chemotherapy 
only 
39 CRT (other 
treatment NR) 
75 (52%) 
Mean 
dose 20Gy 
(5.7) 
2.8  
(1.7) 
NR 
26.7  
(3.4) 
NR 
23.9  
(3.1) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
MRI with DTI 
• The chemotherapy-only group 
performed better than survivors 
treated with CRT in only 3 of 
20 neurocognitive measures 
(verbal selective reminding, 
memory span, visual-motor 
processing speed).  
• All survivors showed reduced 
white and grey matter brain 
fraction when compared with 
controls 
Ehrhardt et 
al., 2018 
Cross-
sectional 
US 
Non-Hodgkin 
Lymphoma 
Population 
norms 
181 
community 
controls 
SJLIFE 
43 (23%) CRT 
(+ other 
treatments NR) 
187 total (23%) 
NR - 
coded as 
dichotomo
us 
variable 
(RT vs no 
RT) 
10.4  
(NR) 
1.8-20.8 
35.7  
(8.9) 
19.3-58.3 
25.5  
(NR) 
10.5-47.7 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
Emotional 
distress, 
health-related 
quality of life 
• Survivors’ intelligence and 
attention were within normal 
limits; however, memory, 
executive function, and 
processing speed were impaired 
in comparison with both 
population norms and 
community controls 
• Treatment type, including 
CRT, was not significantly 
associated with neurocognitive 
performance 
Harila et al., 
2009 
Cross-
sectional 
Longitudinal 
Finland 
ALL 45 healthy 
controls 
20 
chemotherapy 
only  
44 CRT + 
chemotherapy 
16: 18-
23Gy 
22: 24-
25Gy 
6: 30-
48Gy 
5.0  
(NR) 
0.8-15 
26.0  
(NR) 
16-37 
20.0  
(NR) 
10-32 
Intelligence, 
memory, 
attention 
• CRT survivors achieved lower 
scores across verbal and 
performance IQ, memory 
functions, and attention 
compared to the non-irradiated 
group and controls. Non-
irradiated survivors performed 
significantly better, but also 
demonstrated had significant 
impairments in some domains. 
• Significant decline during the 
study period was observed both 
in VIQ and PIQ in the irradiated 
group, but only in VIQ in the 
non-irradiated group 
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Kadan-
Lottick et 
al., 2010 
Cross-
sectional 
US 
1939 ALL 
908 Hodgkin 
disease 
509 Non-
Hodgkin 
lymphoma 
613 Soft tissue 
sarcoma 
tumours 
649 Wilms 
tumour 
1319 other non-
CNS cancers 
382 healthy 
siblings 
CCSS 
452 CRT only 
1663 
chemotherapy 
only 
3178 CRT + 
chemotherapy 
284 No CRT or 
chemotherapy 
5937 total 
(61%) 
Coded as 
No CRT, 
0.1-18Gy, 
>18Gy 
8.5  
(6.0) 
0.0-20.0 
32.2  
(7.6) 
17.0-54.1 
23.7  
(4.5) 
16.0-34.3 
Memory, 
attention, 
executive 
functioning  
 
Emotional 
distress 
• Mean test scores of non-CNS 
cancer survivors varied only 
slightly (<0.5 SD) or not at all 
from the sibling group. Patient 
groups at highest risk were 
those with ALL but only if they 
also received CRT. 
• Chemotherapy was not 
statistically significantly 
associated with self-reported 
neurocognitive functioning after 
adjusting for age, sex, and CRT 
• There was no additional risk 
of impairment after 24Gy of 
CRT compared to under 24Gy 
Krull, 
Brinkman, 
et al., 2013 
Cross-
sectional 
US 
ALL Population 
norms 
 
SJLIFE 
214 
chemotherapy 
only 
353 CRT (other 
treatment NR) 
567 total (62%) 
167: 18Gy 
186: 24Gy 
6.3  
(4.3) 
NR 
33.0  
(NR) 
NR 
26.0  
(NR) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning 
 
Medical 
records 
• Compared with the no CRT 
group, 24Gy CRT group 
showed increased risk for 
impairment in intelligence and 
memory, dependent on age at 
diagnosis. Age at diagnosis 
influenced impact of CRT 
• Mild impairments were also 
demonstrated in 18Gy only and 
chemotherapy only groups, 
particularly in flexibility, 
fluency, and working memory 
• Impairment in executive 
functioning increased with time 
since diagnosis for 24Gy CRT 
group. 
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Krull, 
Zhang, et 
al., 2013 
Longitudinal 
US 
ALL Population 
norms 
SJLIFE 
102 CRT + 
chemotherapy 
102 total 
(100%) 
34: 18Gy 
68: 24Gy 
5.0  
(3.2) 
0.8-15.3 
38.5  
(6.2) 
26.6-54.7 
33.5  
(5.7) 
18.8-46.4 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
Medical 
records 
• Results suggested an initial 
decline in performance IQ after 
CRT, followed by late decline 
in verbal IQ over a follow-up 
period of median 28.5 years 
later, suggesting a progressive 
effect on brain function from 
CRT 
• Decline in verbal IQ was 
associated with current attention 
and reading problems, in 
contrast to variables associated 
with early decline in abilities 
(such as CRT dose, age at 
exposure, and gender) 
Krull et al., 
2014 
Cross-
sectional 
US 
ALL Population 
norms 
SJLIFE 
38 CRT (other 
treatment NR) 
38 (100%) 
19: 18Gy 
19: 24Gy 
2.9  
(1.6) 
NR 
27.5  
(3.5) 
NR 
24.5  
(3.0) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
F-FDG PET 
imaging, 
medical 
records 
• Both 18Gy and 24Gy CRT 
groups demonstrated significant 
impairment on measures of 
vocabulary, reading, 
mathematics, oral naming 
speed, working memory, 
attention span, and cognitive 
flexibility. No differences were 
apparent between groups. 
• Decreased efficiency of the 
frontostriatal brain circuit 
suggested, particularly for those 
treated with 24Gy 
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Link et al., 
2006 
Cross-
sectional 
Sweden 
ALL 44 matched 
healthy 
controls 
44 CRT + 
chemotherapy 
44 (100%) 
Mean 
dose 24Gy 
(18-30) 
4  
(NR) 
1-17 
24.8  
(NR) 
19.8-31.3 
20  
(NR) 
NR 
Intelligence, 
memory, 
executive 
functioning, 
processing 
speed 
 
Quality of 
life, social 
support, 
school 
education, 
questionnaire 
data 
• Compared to controls, ALL 
survivors had significantly 
lower scores in tests of 
vocabulary and general 
knowledge, spatial ability, 
memory and learning, and 
perceptual and psychomotor 
speed. 
• Younger age at CRT treatment 
was associated with poorer 
cognitive outcomes. Survivors 
treated before the age of 6 
showed significantly lower 
scores, but there was wide 
variation within this group 
• Cognitive outcomes were not 
significantly affected by CRT 
dose or time since treatment 
Schuitema 
et al., 2013 
Cross-
sectional 
Netherlands 
ALL 49 healthy 
controls 
 
49 
chemotherapy 
only 
44 CRT + 
chemotherapy 
Mean 
dose 
22.5Gy 
(6.9) 
5.7  
(3.7) 
NR 
31.2  
(4.8) 
NR 
25.4  
(3.2) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning, 
processing 
speed 
 
MRI with DTI 
• CRT survivors demonstrated 
significantly decreased 
fractional anisotropy (FA) 
compared with controls in 
frontal, parietal, and temporal 
white matter (WM) tracts. 
Decreases in FA correlated well 
with neuropsychological 
dysfunction.  
• Younger age at CRT and 
higher dosage were associated 
with worse WM integrity. 
• Accelerated ageing of the 
brain and increased risk of early 
onset dementia are suspected 
after CRT, but not after 
chemotherapy. 
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Schuitema 
et al., 2015 
Cross-
sectional 
Netherlands 
ALL 58 healthy 
controls 
50 CRT + 
chemotherapy 
50 total (100%) 
Mean 
dose 
22.5Gy  
(6.8) 
5.6  
(3.8) 
NR 
31.1  
(4.9) 
NR 
25.5  
(3.1) 
NR 
Intelligence, 
memory, 
attention, 
executive 
functioning 
• Survivors showed impaired 
working memory capacity, 
inhibition, cognitive flexibility, 
visuomotor control, attentional 
fluctuations, and sustained 
attention. 
• Younger age at diagnosis and 
older age at assessment were 
associated with worse cognitive 
performance  
• Female gender and higher 
dose CRT were additional risk 
factors. There was no indication 
of dose effects of chemotherapy 
across cognitive tasks. 
Winqvist et 
al., 2001 
Cross-
sectional 
Finland 
19 ALL 
2 Morbus 
Hodgkin's 
6 other non-
CNS tumours 
22 healthy 
controls 
18 CRT (other 
treatment NR) 
9 No CRT 
(other 
treatments NR) 
27 total (67%) 
Mean 
dose 
29.7Gy 
(9.8) 
8.6  
(5.1) 
1.2-15.4 
18.7   
(3.0) 
16.0-28.6 
9.7  
(5.2) 
3.0-19.5 
Intelligence, 
memory, 
attention 
• Though cancer survivors 
obtained lower test scores in 
intelligence, memory, and some 
motor function tests compared 
to controls, the cancer 
survivors’ IQ scores were not 
defective but reached a normal 
average level.  
• CRT survivors showed more 
difficulty on short-term memory 
tests that demand special 
attention, the reaction time test, 
and Digit Span subtest of the 
WAIS, compared to non-
irradiated survivors and 
controls.  
*BED, biologically effective dose; CCSS, Childhood Cancer Survivor Study; DTI, diffusion tensor imaging; MRI, magnetic resonance imaging NR, not recorded; PIQ, performance IQ; SJLIFE, St 
Jude Lifetime Cohort Study; VIQ, verbal IQ   
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Memory 
Memory is the term given to the processes involved in the encoding, storage, and 
subsequent retrieval of information. Memory measures typically assess episodic 
(memory for events) and/or working memory (ability to hold in mind and mentally 
manipulate information over short periods of time). The most commonly used 
measure in the included studies was the California Verbal Learning Test, second 
edition (CVLT-II). Eighteen studies (5 CNS, 12 non-CNS, 1 both) examined the 
impact of CRT on memory. 
 
CNS studies 
Armstrong et al. (2010) showed that CRT to the temporal region, but not other 
regions, was associated with increased risk for memory difficulties on a self-report 
measure. On behavioural tests, CRT was found to be associated with poorer short-
term and long-term verbal memory in a sample of retinoblastoma survivors relative 
to population norms (Brinkman et al., 2015). Working memory was also found to be 
poorer in brain tumour survivors compared to healthy controls, although working 
memory was also impaired to a lesser extent in the no-CRT group, suggesting the 
presence of other factors affecting memory (King et al., 2017). A further two studies 
concluded that there was an overall effect of both CRT and chemotherapy, 
particularly on encoding ability, but additional analyses revealed no independent 
effect of CRT (Jayakar et al., 2015; Maddrey et al., 2005).  
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Table 5.  
Summary of the Effects of CRT across Neurocognitive Domains 
 
Neurocognitive domains 
 
Intellect Memory Attention Processing 
Speed 
Executive 
Functions 
CNS Studies 
Ailion et al., 2016 
   


Armstrong et al., 2010 
 
 

◊ 
Brinkman et al., 2015 ◊  ◊ ◊ ◊ 
Ellenberg et al., 2009 
 
 

◊ 
Jayakar et al., 2015 + ◊ 
   
King et al., 2017 +   

Maddrey et al., 2005  ◊ ◊ 
 
◊ 
Reimers et al., 2003 
    
Non-CNS Studies 
Armstrong et al., 2013 
 

   
Daams et al., 2012 
 
  ◊ 
Edelmann et al., 2014 ◊      ◊ 
 
 ◊ 
Ehrhardt et al., 2018 ◊ ◊ - ◊ ◊ 
Harila et al., 2009 + 
  

Kadan-Lottick et al., 2010 
 
 


Krull, Brinkman, et al., 2013 +  ◊  ◊ 
Krull, Zhang, et al., 2013 ◊ 
    
Krull et al., 2014  -  - - 
Link et al., 2006 ◊ - - - ◊ 
Schuitema et al., 2013 ◊   

Schuitema et al., 2015 - -  - - 
Winqvist et al., 2010 ◊ 

 ◊ 
= Significant effect of CRT, ◊ = No significant effect of CRT above other treatments, ‘+’ = 
Significant effect of CRT but no impairment,  ‘-’ = Studies did not differentiate specific effects of 
CRT 
 
Non-CNS studies 
Of the 12 studies examining the effects of CRT on memory, five concluded that 
irradiation had adverse effects beyond those of other treatments, with impairment 
demonstrated in: verbal memory and memory interference (Harila et al., 2009); 
verbal and visual delayed memory (Armstrong et al., 2013); learning, short-term and 
long-term recall, and working memory (Krull, Brinkman, et al., 2013); visuospatial 
working memory (Schuitema et al., 2013); and self-reported memory functioning 
(Kadan-Lottick et al., 2010). Of note, Armstrong et al. (2013) and Krull, Brinkman, 
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et al. (2013) only reported impairment after 24Gy CRT (not 18Gy) suggesting an 
interaction with dosage.  
 
Memory impairment was also observed in mixed samples where participants 
received both CRT and chemotherapy, relative to controls (Krull et al., 2014; Link et 
al., 2006; Schuitema et al., 2015). A further three studies identified unique effects of 
CRT on select memory functions in their analysis; in these studies, participants 
treated with CRT and chemotherapy were compared to chemotherapy-only 
subgroups and were found to show poorer scores on measures of sequential working 
memory (Daams et al., 2012), verbal selective reminding, and memory span 
(Edelmann et al., 2014). When examining the differences, Winqvist and colleagues 
(2001) noted that CRT survivors tended to perform more poorly than the no-CRT 
group on more difficult memory tests.  
 
Only one study did not identify CRT as a risk factor for impaired memory in 
regression analysis, despite significant differences between the overall survivor 
group and controls (Ehrhardt et al., 2018). 
 
Conclusions 
In a study examining both CNS and non-CNS cancer survivors, there were no 
differences between CNS and non-CNS survivors who received CRT, and both 
subgroups showed greater impairments than participants who did not receive CRT 
(Ellenberg et al., 2009). Overall, the included studies suggest that memory and 
working memory are similarly affected in adult survivors of different cancer types 
treated with CRT, and may be consistent with the early onset of cognitive ageing. 
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Armstrong and colleagues (2013) even concluded that memory function in their 
sample of ALL survivors was equivalent to an adult older than 69 years in the 
general population. 
 
It is also proposed that the effects of CRT on memory performance interact with 
other factors such CRT dosage, location in the brain, and other concurrent 
treatments. Many studies suggest that chemotherapy also has specific adverse effects 
on memory, although the impact of CRT appears to still surpass that of 
chemotherapy alone, especially on more complex memory tasks (which may require 
other cognitive skills also affected by CRT).  
 
Attention 
Attention can be conceptualised as a limited-capacity process that allows the 
preferential processing of certain sensory information at the expense of other 
available stimuli. Attention is crucial as it influences the efficiency of other functions 
and modulates many other areas of cognition. Fourteen studies (4 CNS, 9 non-CNS, 
1 both) investigated the effects of CRT on aspects of attention.  
 
CNS studies 
All four CNS studies included statistical analysis to differentiate the effects of CRT 
on attention. Two studies concluded that CRT had adverse effects on attention by 
comparing CRT and no-CRT subgroups, although these conclusions are limited as 
King et al. (2017) used only a digit span forwards task and Armstrong et al. (2010) 
used a self-report measure of task efficiency to measure attention. Two further 
studies which used a validated continuous performance task (CPT) found no 
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association between CRT and performance (Brinkman et al., 2015; Maddrey et al., 
2005). 
 
Non-CNS studies 
Of the nine non-CNS studies, five studies demonstrated some independent effects of 
CRT on attention (Daams et al., 2012; Kadan-Lottick et al., 2010; Krull et al., 2014, 
Schuitema et al., 2013; Schuitema et al., 2015), although two of these found only 
selective effects on attention span (Krull et al., 2014) and attentional fluctuations 
during a sustained attention task (Daams et al., 2012). A further two studies 
suggested that CRT and chemotherapy equally impair attention relative to controls 
(Edelmann et al., 2014; Krull, Brinkman, et al., 2013), although this was limited to 
measures of attention variability for Edelmann et al., (2014), with no significant 
effects of either treatment on sustained or focused attention. The remaining two 
studies, which did not analyse CRT and chemotherapy separately, concluded that 
attention was within normal limits in non-CNS survivors (Ehrhardt et al., 2018; Link 
et al., 2006). 
 
Conclusions 
Ellenberg et al. (2009) examined both CNS and non-CNS survivors from the 
Childhood Cancer Survivor Study. They concluded that, although CRT impacts all 
cancer survivors, it has greater effects in survivors of CNS cancers; they found that 
CNS CRT survivors reported greater task efficiency impairment than the non-CNS 
CRT survivors, who in turn reported greater impairment than survivors who did not 
receive CRT. In contrast, no strong patterns are present in the results of the included 
CNS studies. The mixed results may somewhat be explained by the variety of 
attention tasks measuring different aspects of attention.  
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Processing Speed  
Processing speed is typically conceptualised as the rate at which a person can 
complete mental operations. Twelve studies (3 CNS, 9 non-CNS) investigated the 
effects of CRT on processing speed.  
 
CNS studies 
Of the three studies that examined adult survivors of childhood brain tumours, two 
concluded that CRT had an adverse effect on processing speed (Ailion et al., 2016; 
King et al., 2017). The remaining study failed to find any effect (Brinkman et al., 
2015). All three studies employed statistical analysis to differentiate specific effects 
of CRT, although King et al. (2017) reported effect sizes only.  
 
Non-CNS studies 
Of the nine studies that examined the effects of CRT on processing speed in non-
CNS cancers, three indicated some independent adverse effect of CRT; two of these 
studies compared subgroups of participants receiving CRT and chemotherapy, 
chemotherapy only, and healthy controls, and concluded that processing speed was 
significantly slower for the CRT subgroup (Edelmann et al., 2014; Schuitema et al, 
2013). The other compared irradiated and non-irradiated participants and found a 
significant difference in performance on the digit symbol coding subtest of the WAIS 
(Winqvist et al., 2001). A further three studies suggested that processing speed is 
impaired by treatment with both CRT and chemotherapy but did not differentiate 
treatment type (Krull et al., 2014; Link et al., 2006; Schuitema et al., 2015). 
 
The remaining three studies failed to identify any specific effects of CRT on 
processing speed. Daams et al. (2012) found no significant differences between 
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participants treated with CRT and chemotherapy, with chemotherapy only, and 
controls, although the measure they used was primarily validated as a measure of 
executive function.  The other two studies included CRT as a factor in regression 
analyses exploring risk factors associated with processing speed; although Ehrhardt 
et al. (2018) did not identify any significant association, Krull, Brinkman, et al. 
(2013) propose gender as an equal and interacting risk factor, as their findings 
suggested that processing speed was only affected in female participants who had 
received at least 24Gy CRT. 
 
Conclusions 
Taking CNS and non-CNS studies together, it seems that processing speed is 
vulnerable to the effects of cancer treatment in childhood, and the impact mostly 
endures to adulthood. Slowed processing speed is observed across studies where 
participants have had CRT and chemotherapy, and CRT alone, especially on visual-
motor tasks but also on pure tasks of processing speed which do not depend on motor 
functioning. Additional factors such as gender and chemotherapy are suggested, 
however, two studies with effective designs that included a chemotherapy-only group 
(therefore providing the best evidence for some independent effect of CRT) indicated 
that performance remains significantly poorer in participants who received CRT. 
 
General Executive Functions 
General executive functions encompass aspects of global executive functioning that 
are separate from the central components of attention, working memory, and 
processing speed. Various measures of cognitive flexibility, fluency, inhibition, and 
self-reported emotional regulation and organisation were used across the fourteen 
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studies (4 CNS, 10 non-CNS) that examined the impact of CRT on executive 
functions.  
 
CNS studies 
Three CNS studies found that their overall survivor sample was impaired relative to 
norms on measures of cognitive fluency (Brinkman et al., 2015), verbal fluency and 
set-shifting (Maddrey et al., 2005), and self-reported organisation and emotion 
regulation (Ellenberg et al., 2009), but additional analyses revealed no specific 
effects of CRT. Armstrong et al. (2013) used the same self-report measure, and 
found no significant association between CRT to any brain region and emotional 
regulation or organisation. 
 
Non-CNS studies 
Whilst three studies found that cognitive fluency, flexibility and inhibition were 
poorer in a broad group of participants who received CRT and chemotherapy 
compared to controls (Krull et al., 2014; Link et al., 2006; Schuitema et al., 2015), 
they did not include analysis to differentiate the effects of CRT and chemotherapy. 
Of the seven non-CNS studies that did, three concluded that CRT had specific 
adverse effects on accuracy of set-shifting (Daams et al., 2012), inhibition and visual 
attention (Harila et al., 2009), and self-reported organisation but not emotion 
regulation (Kadan-Lottick et al., 2010). The remaining four studies did not identify 
any impact of CRT exceeding that of chemotherapy (Edelmann et al., 2014; Ehrhardt 
et al., 2018; Krull, Brinkman, et al., 2013; Winqvist et al., 2001). However, Krull, 
Brinkman, et al. (2013) suggested that survivors treated with a higher CRT dosage 
(24Gy) were at greater risk for executive functioning impairment with increasing 
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years from diagnosis, such that the risk was six times greater 45 years after treatment 
compared to the no-CRT group. 
 
Conclusions 
There was no specific impact of CRT on general executive functions in CNS studies. 
Non-CNS studies suggested some increased difficulty with set-shifting and inhibition 
related to CRT but it is difficult to distinguish the effects of different treatments on 
performance. Executive functioning may also be increasingly vulnerable over time 
for survivors who received CRT.  However, it is important to consider other factors, 
for example two studies found that general executive functions were equally or more 
strongly affected by emotional distress than CRT (Ehrhardt et al., 2018; Kadan-
Lottick et al., 2010). 
 
Other Risk Factors 
The present review also sought to answer whether cognitive outcomes are related to 
age at diagnosis, time since treatment, and CRT dosage. Results are summarised in 
Table 6.  
 
Age at diagnosis 
Fifteen (7 CNS, 8 non-CNS) of 21 studies examined the effects of age at diagnosis 
on cognitive functioning in adulthood. 
 
CNS studies 
The two CNS studies that investigated the interaction between CRT and age at 
diagnosis indicated that, among participants who had received CRT only, an earlier 
age of diagnosis was associated with poorer performance on measures of processing 
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speed (Ailion et al., 2016) and working memory (King et al., 2017).  
 
Table 6.  
Summary of Effects of Risk Factors 
  Risk Factors  
 
Age at 
Diagnosis 
Time since 
treatment 
CRT Dosage 
CNS Studies 
Ailion et al., 2016 
  
Armstrong et al., 2010 ◊ 
 

Brinkman et al., 2015 
  
Ellenberg et al., 2009 ◊ ◊ 
Jayakar et al., 2015 
   
King et al., 2017 
  
Maddrey et al., 2005   ◊ 
Reimers et al., 2003  ◊ 
Non-CNS Studies 
Armstrong et al., 2013 ◊ ◊ 
Daams et al., 2012 
   
Edelmann et al., 2014 
   
Ehrhardt et al., 2018 
   
Harila et al., 2009 
  
◊ 
Kadan-Lottick et al., 2010   
Krull, Brinkman, et al., 2013   
Krull, Zhang, et al., 2013 ◊ ◊ ◊ 
Krull et al., 2014 
  
◊ 
Link et al., 2006  ◊ ◊ 
Schuitema et al., 2013   ◊ 
Schuitema et al., 2015   
Winqvist et al., 2001 
  
= Significant effect, ◊ = No significant effect 
 
Although a further three studies suggested that age at diagnosis had significant 
effects on memory (Brinkman et al., 2015), executive functioning (Maddrey et al., 
2005), and IQ (Reimers et al., 2003), they did not control for CRT as a risk factor in 
their analyses. Reimers et al.’s (2003) separate linear regression models instead 
proposed that CRT and age at diagnosis, in addition to shunt and tumour location, 
constitute four “approximately additive” factors (p. 33). Of note, Brinkman et al.’s 
(2015) findings in retinoblastoma survivors were in contrast with the broader cancer 
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survivor literature as they indicated that diagnosis before 1 year of age was related to 
better neuropsychological performance. However, the other two studies found 
correlations such that younger age at diagnosis was related to greater cognitive 
impairment in adulthood. A further two studies measured self-reported 
neurocognitive functioning and found no significant association with age at diagnosis 
(Armstrong et al., 2010; Ellenberg et al., 2009).  
 
Non-CNS studies 
Of the eight non-CNS studies, only two failed to find any effect of age at diagnosis. 
In these studies, regression analyses did not find any association between age at 
diagnosis, CRT dose, and memory deficits (Armstrong et al., 2013) or decline in 
verbal IQ (Krull, Zhang, et al., 2013). The other six studies concluded that younger 
age at diagnosis was related to greater impairment in cognitive functioning in 
adulthood, largely affecting IQ, memory, and motor/visuomotor functioning, 
although only three examined the effects of age at diagnosis in participants who 
received CRT in particular (Krull, Brinkman, et al., 2013; Link et al., 2006; 
Schuitema et al., 2013). Across studies with significant findings, three proposed a 
clear age threshold of five (Winqvist et al., 2001) or six years of age (Kadan-Lottick 
et al., 2010; Link et al., 2006) under which treatment was associated with increased 
risk of impairment. One further study suggested that risk gradually decreased with 
increasing age at diagnosis (Krull, Brinkman, et al., 2013). However, upon further 
examination, Link et al. (2006) found wider variation in performance in participants 
receiving CRT at younger ages, and therefore speculated that this result may reflect a 
small subset of participants with particularly low scores. 
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Conclusions 
The majority of studies suggested that younger age at diagnosis (and subsequent 
treatment) was associated with poorer cognitive outcomes in later life, for both CNS 
and non-CNS cancers. There is insufficient evidence to suggest that this effect is 
specific to CRT as many of the included studies did not differentiate CRT survivors. 
Nonetheless, two studies suggest an interaction between age at diagnosis and CRT 
and one further study suggests that they are equal risk factors for cognitive 
impairment. There is also a suggestion of a critical threshold around age five or six 
years of age in several studies, although this is opposed by studies that found 
negative correlations between age at diagnosis and later cognitive functioning. 
 
Time since diagnosis  
Ten studies (3 CNS, 7 non-CNS) examined the impact of time since 
diagnosis/treatment or age at assessment on cognitive outcomes. Of the five studies 
that investigated time since diagnosis specifically, only one suggested that 
impairment in executive functioning increased with time since diagnosis (Krull, 
Brinkman, et al., 2013). Alternatively, of the five studies that investigated age at 
assessment, two concluded that older age at assessment was particularly associated 
with poorer visuomotor abilities (Schuitema et al., 2013; Schuitema et al., 2015), two 
CNS studies failed to find any effect (Ellenberg et al., 2009; Reimers et al., 2003), 
and one conversely concluded that younger age at assessment was associated with 
increased risk of impairment, but only on the task efficiency dimension of a self-
report measure of neuropsychological functioning (Kadan-Lottick et al., 2010). In 
sum, findings were mixed depending on whether time since diagnosis or age at 
assessment was investigated. 
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CRT dosage 
Thirteen studies (3 CNS, 9 non-CNS, 1 both) investigated the effects of increasing 
CRT dose on cognitive functioning in long-term childhood cancer survivors.  
 
CNS studies 
Of three CNS studies, two concluded that higher CRT dosage was related to 
increased impairment; Armstrong et al. (2010) found location and dose-response 
effects, with higher dose CRT to the temporal region (but not other regions) 
predicting increased problems with memory and task efficiency. Reimers et al. 
(2003) utilised BED (a measure of biologically effective dose), which was 
significantly negatively correlated to verbal IQ, also showing a dose-response effect. 
The remaining study did not find any significant effect of CRT dose (Maddrey et al., 
2009). 
 
Non-CNS studies 
Five studies compared ALL survivors who received either 18Gy or 24Gy, reflective 
of changing treatment protocols over time. Of these studies, two suggested that both 
18Gy and 24Gy subgroups demonstrated significant impairment, with no additional 
risk of impairment for CRT doses above 24Gy (Kadan-Lottick et al., 2010; Krull et 
al., 2014). Another two studies found statistically significant impairment in 
participants who had received 24Gy (but not 18Gy) in immediate recall (Armstrong 
et al., 2013), and intelligence, memory, and attention (Krull, Brinkman, et al., 2013), 
although the latter study also found academic impairment after 18Gy and 
chemotherapy. The remaining study by Harila et al. (2009) did not find any 
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significant difference in IQ amongst participants treated with 18Gy or 24Gy, and 
both subgroups achieved scores in the average range.  
 
A further two non-CNS studies with mean CRT dose 22.5Gy also concluded that 
higher CRT dosage was an additional risk factor for impaired neurocognitive 
outcomes (particularly visuomotor abilities) and poorer white matter integrity 
(Schuitema et al., 2015; Schuitema et al., 2013). Only two studies of ALL survivors 
failed to identify any association between similar CRT doses and later cognitive 
functioning (Krull, Zhang, et al., 2013; Link et al., 2006). 
 
Finally, Ellenberg et al. (2009) compared CNS survivors treated with mean dose 
36.3Gy CRT, non-CNS survivors who received 24Gy CRT, and non-irradiated non-
CNS survivors across four self-reported cognitive factors. Findings suggested a dose-
response effect on task efficiency and significant effects of CRT on memory, though 
there was no difference in memory scores between CRT subgroups who received 
different doses. 
 
Conclusions 
Across thirteen studies, nine (69%) found dose-response effects of CRT on 
neuropsychological functioning, suggesting similar effects across cancer types. It is 
important to note that mean CRT dosage was generally higher across CNS studies 
than non-CNS studies, although many studies examining ALL survivors also 
suggested impairment still exists at lower doses. There was an emerging consensus 
that participants were more impaired across several domains after 24Gy, with some 
studies suggesting no effect of 18Gy except on more complex neuropsychological 
processes such as fluency and flexibility. Some studies further suggested that the 
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effects of 18Gy were similar to those observed in participants treated with 
chemotherapy, indicating some non-specific treatment effects. However, no dose 
effects of chemotherapy were observed in participants who received both CRT and 
chemotherapy, suggesting that the effects of chemotherapy are nullified by the much 
larger effects of CRT.  
 
Anatomical Correlates 
Seven studies (2 CNS, 5 non-CNS) also used neuroimaging to identify specific 
effects of CRT on brain structures and activity, and their relationship to cognitive 
functioning. Of studies that examined brain structures, two found that smaller (right) 
hippocampal volume was associated with memory impairment in ALL and brain 
tumours survivors (Armstrong et al., 2013; Jayakar et al., 2015). Memory problems 
were also associated with CRT to the temporal region in one self-report CNS study 
(Armstrong et al., 2010) and a further non-CNS study which specified problems with 
immediate memory (Armstrong et al., 2013).   
 
Furthermore, several studies suggested that participants treated with CRT and 
chemotherapy showed lower total brain volume (Armstrong et al., 2013; Edelmann et 
al., 2014; Jayakar et al., 2015), however Jayakar and colleagues (2015) proposed that 
whole brain volume is affected in all brain tumour survivors and only subcortical 
structures are uniquely affected by CRT. This conclusion is supported by Reimers et 
al.’s (2009) findings which showed that tumour site in the cerebral hemisphere (but 
not subcortical structures of the posterior fossa or the midbrain) was a strong 
predictor of lower cognitive function in a mixed sample that did not differentiate 
CRT and chemotherapy. Conversely, Krull et al. (2014) suggested a feedback loop 
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whereby increased activation in subcortical regions may be due to reduced inhibition 
from cortical regions, affecting the overall efficiency of neurocognitive processes. 
Daams et al. (2012) detected some compensatory activity in other brain regions 
(familiar in normal ageing), but this was not sufficient to improve cognitive 
functioning.  
 
A further two studies concluded that ALL survivors treated with CRT demonstrated 
a reduction in white matter volume and thickness (particularly affecting fibre tracts 
in frontal, temporal, and parietal regions which can have widespread effects on 
cognition when damaged) and memory impairment, consistent with a pattern of early 
or accelerated ageing (Edelmann et al., 2014; Schuitema et al., 2013).  
 
Discussion 
 
Although there is a substantial body of literature documenting a range of cognitive 
deficits in childhood cancer survivors who received CRT, few studies to date have 
examined the impact of CRT on cognition beyond ten years. This review has 
examined neurocognitive outcomes of childhood cancers an average of 22 years 
post-treatment across 21 studies. Differentiating risk factors for adverse 
neurocognitive outcomes is a complex process, as evidenced by the wide variation 
across studies in methods of analysing and reporting specific effects of CRT. 
Nonetheless, it is possible to draw some conclusions regarding the effects of CRT on 
cognitive functioning in adult survivors of childhood cancers. 
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Neurocognitive outcomes in CRT survivors 
Overall findings across five domains of cognitive functioning suggest that CRT is 
more likely to have unique enduring effects on memory, attention, and processing 
speed than intelligence and general executive functions.  
 
Whilst studies were mixed in their conclusions regarding the effects of CRT beyond 
other treatments on intellectual functioning, the majority found that IQ remained 
within the average range, consistent with reviews of the paediatric literature (Roman 
& Sperduto, 1995). This is an important distinction to make as, although it is possible 
that CRT may result in significant declines in IQ and reduced cognitive reserve over 
time, there is little evidence that IQ is impaired relative to population norms. 
Findings from current studies up to 30 years post-treatment support non-linear 
models indicating an attenuation in decline in IQ over time, such as the model 
proposed by Spiegler et al. (2004), and further demonstrate that continued decline is 
only evident in survivors treated with CRT (Harila et al., 2009). Furthermore, there is 
also evidence in the present review for idiosyncratic trajectories in cognitive 
functioning; Krull, Zhang, et al. (2013) found that almost half of their ALL survivor 
sample treated with CRT did not demonstrate any significant decline in IQ, contrary 
to the overall finding of significant decline. Individual differences are also found in 
the paediatric literature, with some studies even reporting improvement in several 
participants (e.g. Vigliani, Sichez, Poisson, & Delattre, 1996). 
 
The profile of memory problems identified in adult survivors of childhood cancers 
treated with CRT is largely consistent with early onset of cognitive ageing. 
Specifically, studies indicate that delayed and working memory are most affected, 
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suggesting ineffective encoding or consolidation of new information. The present 
review also suggested that chemotherapy may affect basic memory skills in adult 
survivors, and the effects of CRT are specific to more complex memory tasks. This 
pattern of impairment is also observed in the development of dementia in older 
adults, with more complex tasks affected by early declines. Some studies have even 
suggested that this profile has clinical utility for early detection, for example Welsh 
and colleagues (1991) found that scores on a delayed recall task differentiated early 
Alzheimer’s Disease patients from healthy controls with better than 90% accuracy. 
However, the difference between dementia sufferers and the current population is in 
functional impairment; Armstrong et al. (2013) did not find a difference in 
employment rates between participants treated with different doses of CRT and 
therefore suggested that deficits in middle adulthood may be more reflective of mild 
cognitive impairment, which is often considered to be a precursor to dementia 
(Petersen, 2004). 
 
Findings also suggested that attention may be specifically affected by CRT; attention 
span and variability were affected in some studies, especially in non-CNS survivors. 
Processing speed was also affected by CRT, particularly on visuomotor tasks. A key 
consideration interpreting these results is the interaction of different cognitive 
abilities. Whilst study of cognition necessitates that it is divided into discrete 
domains of functioning, it is likely that domains are inter-related i.e. deficits in one 
domain may have a significant impact on other domains. Early information 
processing models proposed that the brain has a limited capacity to input, store, and 
respond to external information and other domains are therefore reliant on attention 
(Broadbent, 1958). More recent models developed from studies with childhood brain 
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tumour survivors have also suggested that processing speed, attention, and working 
memory are interrelated, and have further effects on IQ (King et al., 2017; Palmer, 
2008; Wolfe et al., 2012). The results of included studies are largely consistent with 
these models, as deficits are identified across processing speed, attention, and 
working memory, and Krull, Zhang, et al. (2013) found that observed decline in IQ 
was more associated with current attention deficits than traditional risk factors such 
as CRT dose or age at diagnosis.  
 
Finally, examination of general executive functions such as fluency, flexibility, 
organising, and inhibition did not highlight significant effects of CRT. A minority of 
studies suggested some effect on set-shifting, although this may be related to deficits 
in attention and processing speed. The same studies also found a significant impact 
of emotional distress on executive functioning, suggesting that CRT is not a primary 
risk factor in predicting later executive impairment. 
 
Risk factors 
The majority of included studies suggested that younger age at diagnosis continues to 
be associated with poorer neurocognitive outcomes up to 34 years after treatment, 
consistent with robust findings in the paediatric literature (e.g. Duffner, 2010). 
However, it is not clear whether this effect is specific to CRT treatment, as many of 
the included studies examined mixed treatment samples. It is possible that the effects 
of age at diagnosis are not specific to CRT treatment as this risk factor has also been 
shown to predict adverse effects of chemotherapy (Krappmann et al., 2007). 
Furthermore, closer inspection of data in the younger subgroup was also found to be 
more scattered, suggesting that severe damage may only occur in a minority of 
participants treated at a younger age. 
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When time since diagnosis was examined, no associations were indicated with later 
neurocognitive outcomes. However, significant relationships between age at 
assessment and impairment, particularly in visuomotor functioning, were observed. 
Crucially, Ellenberg et al. (2009) noted that age at diagnosis and age at assessment 
have independent effects on cognitive outcomes, and therefore suggested that by 
using time since diagnosis in studying the effects of ageing, the magnitude of both 
the ageing-effect and the impact of age at diagnosis are masked. It is therefore 
possible that studies using time since diagnosis failed to detect ageing effects as a 
result of not controlling for age at diagnosis, rather than because there was no effect. 
Further research in this population is required examining age at assessment to clarify 
the current mixed findings. 
 
Dose-response effects of CRT were also observed across most studies, consistent 
with findings from reviews examining effects of CRT earlier in the lifespan 
(Armstrong et al., 2004; Roman & Sperduto, 1995). Moreover, results from non-
CNS studies comparing survivors treated with 18Gy and 24Gy indicated that, 
although most cognitive domains are affected after 24Gy, more complex 
neuropsychological abilities may be especially sensitive to CRT, as they were 
affected after lower doses. 
 
CRT and cancer type 
Given that both CNS and non-CNS studies found dose-response effects, and average 
doses were higher in CNS studies, it could be hypothesised that CNS survivors 
would demonstrate greater impairment. Certainly, deficits in IQ were only found in 
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CNS studies, however no notable differences were observed between CNS and non-
CNS survivors in memory, attention, and processing speed domains as a result of 
CRT. Minimal differences were also observed in risk of cognitive impairment 
resulting from age at diagnosis or time since assessment according to cancer type. 
 
Although performance on neuropsychological tests did not differ with cancer type, 
CNS survivors may have been more functionally impaired; Gurney et al. (2009) 
found that adult survivors of childhood CNS cancer show greater deficits in 
educational attainment, employment, and marital status than either sibling controls or 
non-CNS survivors. Further research into the psychosocial impact of childhood 
cancer treatment is necessary to clarify the differences in late effects according to 
cancer type. 
 
Mechanisms of CRT resulting in cognitive decline 
Although only a limited array of studies were included in the present review, which 
used diverse measures to examine neurological structures and mechanisms 
underlying CRT, several studies suggested that memory impairment was associated 
with frontal and temporal cortical thickness and smaller hippocampal volume. These 
findings are consistent with neuroimaging studies of childhood brain tumour 
survivors which revealed abnormal patterns of hippocampal development after 
irradiation, particularly in the right hippocampus (Nagel et al., 2004; Riggs et al., 
2014). 
 
Furthermore, there was some consensus that poorer neuropsychological performance 
was associated with reduced white matter integrity and volume. Specifically, poorer 
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white matter integrity in frontal, parietal, and temporal tracts was highlighted; these 
tracts are known to myelinate at a later age than other brain regions and may 
therefore somewhat explain the effects of age at diagnosis on later cognitive 
functioning (Tau & Peterson, 2009). There were also notable similarities between 
adult survivors of childhood cancers and Alzheimer’s Disease patients in brain 
structure, white matter (as measured by fractional anisotropy [FA]), and oscillatory 
activity (Daams et al., 2012; Parente et al., 2008). Memory function in particular, 
was related to higher FA (Edelmann et al., 2014). Higher FA was also directly 
related to age at assessment, suggesting that white matter continues to decline as the 
brains of childhood cancer survivors age. 
 
Currently, there is mixed evidence regarding whether poorer neurocognitive 
outcomes are a result of CRT specifically, and the majority of studies included in this 
review found alterations in white matter regardless of treatment type. There have 
been several proposed mechanisms by which cancer treatment may affect the brain 
including; glial scarring and axonal injury, vasculopathy leading to ischaemia, 
decreased myelin, and white matter compaction. There is evidence that both 
chemotherapy and CRT can: kill oligodendrocytes (myelinating cells) resulting in 
reduced myelin (Kurita et al., 2001; Smith, 1975); cause vasculopathy leading to 
ischaemia and white matter necrosis (Morris, Bywaters, & Hopewell, 1996); and 
limit neural repair by damaging progenitor cells (differentiating cells) which usually 
maintain white matter integrity and stimulate hippocampal neurogenesis (Fukuda et 
al., 2005). Furthermore, these patterns of impairment may not be specific to any type 
of cancer treatment as increased FA has also been observed after brain injury (e.g. 
Wilde et al., 2008). 
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Methodological limitations of included studies 
It is important to consider limitations in the methodology of the discussed studies. 
Although the vast majority of the included studies utilised standardised 
neuropsychological tasks, two studies measured self-reported neurocognitive 
functioning. It is questionable whether these measures are representative of ability, 
though some studies have suggested that self-reported cognitive data correlate with 
performance-based assessment and neuroimaging (De Groot et al., 2001; Mahone, 
Martin, Kates, Hay, & Horska, 2009). 
 
Additionally, the majority of studies used retrospective designs, and therefore 
information regarding premorbid or baseline neurocognitive functioning was not 
available. Cross-sectional designs may fail to detect an effect of CRT if individuals 
with high premorbid IQ (and associated greater cognitive reserve) are included as 
significant decline may not result in impairment at the point of evaluation. Indeed, 
this disparity was highlighted in the present results, and therefore findings from 
retrospective studies should be interpreted with a degree of caution. Furthermore, 
additional studies have highlighted the presence of impairment at baseline due to the 
malignancy itself, further confounding the effects of CRT (Armstrong et al., 2004). 
 
Other limitations within the included studies are more concerned with feasibility 
within a very complex area of study. Most patients who undergo CRT also receive 
other medical interventions that are proposed to also have adverse effects on 
cognitive functioning including surgery and chemotherapy. Ideally, treatments would 
be isolated and compared to each other and healthy controls, yet it is infinitely more 
common that patients receive at least two treatment modalities. Even in studies 
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comparing participants who received a combination of CRT and chemotherapy to 
participants who only received chemotherapy, it is difficult to conclude that greater 
effects in the former group are attributable to CRT. Moreover, individual tolerance to 
CRT is variable, and may interact with concomitant chemotherapy to lower 
impairment thresholds beyond the effects of chemotherapy alone (Rottenberg, 1991). 
Furthermore, assignment to particular treatment protocols is likely to be influenced 
by factors such as diagnosis, and severity of disease, thus differences in cognitive 
outcomes could be attributable to pre-existing differences rather than treatment 
effects (Roman & Sperduto, 1995). Although it is not possible to entirely control for 
the many interrelated risk factors in measuring neurocognitive outcomes, wider use 
of multivariate analysis better allows for the study of these interactions; 14 of the 21 
included studies used regression analyses in differentiating the effects of CRT and 
may therefore have drawn more reliable conclusions about its specific effects. 
 
Implications and future directions 
Knowledge of likely deficits and risk factors is important for researchers as they 
strive to reduce neurotoxicity whilst maintaining treatment effectiveness. In light of 
findings regarding the effects of CRT at younger ages, recommendations have been 
made to avoid or delay CRT in brain tumour patients under three years old, though 
the outcomes of these studies are mixed (Bouffet, 2010; Geyer et al., 2005; 
Heideman, 2001). Other efforts made to reduce the impact of identified risk factors 
include reducing CRT dosage (Duffner, 2010), and use of conformal radiotherapy 
which uses 3D imaging to attempt to spare surrounding normal tissues (Conklin, Li, 
Xiong, Ogg, & Merchant, 2008). 
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Recently, emphasis is shifting towards neuroimaging research that may improve 
understanding of mechanisms of CRT damage. Advances in understanding of the 
underlying biology of cancers may allow future treatments to be tailored accordingly, 
for example evidence is increasing that medulloblastoma is comprised of a group of 
molecularly distinct tumours rather than a single disease entity, which may require a 
unique treatment protocol (Gajjar et al., 2004). Current neuroimaging studies 
indicating accelerated ageing in the white matter of adult survivors of childhood 
cancers also highlight the need to provide continued follow-up for this population. 
Adult survivors may also benefit from early screening and/or diagnosis of mild 
cognitive impairment as early detection may facilitate access to cognitive 
interventions such as the 12-week computerised intervention targeted at working 
memory developed by Hardy and colleagues (2011). 
 
Although findings of the present review suggest late effects on multiple cognitive 
domains and neuroanatomic substrates, the predictability of these deficits continues 
to be reduced by multiple confounding factors, including individual factors. 
Armstrong et al. (2004) propose that individual vulnerability to CRT is complex, 
leading to severe damage in only a minority of patients. Longitudinal studies are 
needed to fully characterise enduring deficits and determine factors that place 
individual patients most at risk. Future research should also use multidisciplinary 
measures to provide convergent evidence of deficits and contributing mechanisms. 
 
Limitations  
There are several limitations of the present review that must be considered. Firstly, 
fewer CNS studies met inclusion criteria than non-CNS studies, therefore the 
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conclusions drawn from these may be less reliable.  Secondly, only three risk factors 
are considered in detail, which may not fully explain the variation in findings; other 
risk factors such as tumour location and gender may also have shown significant 
effects. Additionally, although studies which compared to chemotherapy-only 
subgroups in their design were included, findings were not compared to separate 
studies of survivors who received chemotherapy alone. Moreover, the present review 
did not distinguish between different chemotherapeutic agents despite evidence to 
suggest that different ALL chemotherapy treatment regimens (without CRT) result in 
different rates of acute neurotoxicity and leukoencephalopathy according to factors 
such as exposure with repeated intravenous methotrexate (MTX), and choice and 
timing of triple intrathecal therapy (Mahoney et al., 1998). Finally, given that many 
of the included studies examine survivors treated under historic ALL protocols, the 
findings are not generalisable to the current ALL population. However, findings 
continue to be relevant to brain tumour survivors treated on contemporary protocols.  
 
Conclusions 
 
Despite ongoing difficulties differentiating the effects of CRT from other treatments 
and associated risk factors, there is growing evidence to suggest that CRT continues 
to specifically adversely affect memory, processing speed, and attention in adult 
survivors of childhood cancers beyond the effects of chemotherapy alone. 
Furthermore, younger age at diagnosis and CRT dosage continue to be significant 
risk factors for adverse cognitive outcomes in older survivors, regardless of cancer 
type. However, many additional factors need to be considered in the interpretation of 
these findings, including the significant interactions between different cognitive 
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domains, individual differences, and multiple risk factors that may predict cognitive 
decline years after treatment.  
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Abstract 
 
Aims: The aim of this study was to provide a preliminary overview of how receiving 
cranial radiotherapy (CRT) during adolescence affects neurocognitive, social, and 
psychological functioning in adulthood. Three additional risk factors (radiotherapy 
dosage, time since treatment completion, and additional treatments) were also 
evaluated. 
 
Method: Twenty-five adult survivors of brain tumours treated with CRT were 
compared with a control group of 17 survivors of non-CNS malignancies treated 
with radiotherapy elsewhere in the body. Participants completed a brief IQ 
assessment, an intrusive imagery interview, and self-report questionnaire measures of 
social functioning, depression, and anxiety. 
 
Results: Few differences were identified between survivors treated with CRT and 
controls across domains of social and psychological functioning, though participants 
treated with CRT reported significantly greater problems with memory, and were 
five times more likely than controls to be single. Results indicated generally positive 
social adjustment, and IQ scores and levels of depression and anxiety were 
comparable to the normal population. Total radiotherapy dosage and receiving 
chemotherapy in addition to radiotherapy were significant predictors of IQ, 
regardless of where RT was administered in the body. Time since treatment and 
surgery did not predict late effects across any domain.  
 
 
79 
 
Conclusions: Although results may be suggestive of a protective effect of age such 
that survivors treated with CRT during adolescence may not necessarily suffer the 
same adverse effects as those irradiated during childhood, this conclusion must be 
interpreted with great caution, in view of substantial methodological limitations. 
Implications and the need for further research are discussed.
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Introduction 
 
Onset of cancer in adolescence is a relatively rare occurrence, accounting for less 
than 2% of cancers in the US and less than 1% in Europe (Birch, Alston, Quinn, & 
Kelsey, 2003; Bleyer, Viny, & Barr, 2006; Cancer Research UK, 2018). Although 
distinct in tumour epidemiology, incidence, and survival rates, there is a common 
trend for the adolescent and young adult age group to be incorporated with either 
childhood or older adult populations, thus the experience of cancer in adolescence 
remains poorly understood. 
 
Alongside rising incidence rates in adolescent cancers (Cancer Research UK, 2018), 
advances in medical technology, including radiotherapy (RT), have resulted in 
improved survival rates since the 1970s (Siegel, Miller, & Jemal, 2018). 
Consequently, the long-term or late effects of these treatments are becoming an 
increasingly relevant concern for a growing population of adult survivors of 
adolescent cancers. Despite the well-established literature on the adverse outcomes 
of cranial radiotherapy (CRT) for survivors of childhood cancers, few studies to date 
have distinguished the unique psychosocial and neurocognitive outcomes of cancer 
when diagnosed in the teenage years.  
 
Developmental characteristics of adolescents 
Adolescence is typically experienced as a turbulent stage of development, 
characterised by a multitude of physical, neurological, emotional, social, and 
cognitive changes. Although cancer patients of all ages are said to experience a 
universal set of disruptions (Rowland, 1990), individuals diagnosed with cancer 
81 
 
during adolescence are likely to face additional challenges due to the important 
developmental ‘tasks’ associated with this period.  
 
Psychosocially, adolescence is concerned with increasing autonomy and shifts in 
attachment from parents to peers, thus socialising with peers becomes increasingly 
important (Ryan, 2001). Adolescents are also expected to develop a personal value 
system and sense of self (Erikson, 1956), alongside an increased ability for abstract 
reasoning and logical thought (Piaget, 1952). Hormonal changes occurring during 
this period lead to alterations in physical appearance and body image, and emerging 
intimate relationships, which are often accompanied by increased anxiety and self-
consciousness (Buchanan, Eccles, & Becker, 1992). In addition to the significant 
psychosocial and hormonal challenges faced during this period, the adolescent brain 
also undergoes significant reorganisation, beginning in puberty and continuing into 
early adulthood (Konrad, Firk, & Uhlhaas, 2013). This reorganisation primarily 
involves maturation of white matter networks which support the development of 
advanced cognitive abilities (Giedd et al., 1999; Giedd et al., 1996; Konrad et al., 
2013; Mulhern et al., 2001). Whilst the high cortical plasticity of the adolescent brain 
is crucial for the intellectual and emotional development associated with this life 
stage, it may also increase vulnerability to harm from treatments such as CRT.  
 
Current knowledge of the late effects of CRT 
Late effects, as distinguished from acute effects, are those that emerge months or 
years after completion of treatment, and are assumed to be chronic and progressive in 
nature. It is widely accepted within the paediatric literature that children receiving 
cranial or craniospinal radiotherapy are at higher risk for impaired functioning later 
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in life, though the applications of this research to survivors of adolescent cancers is 
yet unclear.  
 
Neurocognitive functioning 
Since the 1980s, many reviews have evaluated the impact of CRT on cognitive 
functioning in survivors of childhood brain tumours and acute lymphoblastic 
leukaemia (ALL). Although late effects have been reported across many domains of 
neuropsychological functioning, IQ scores have historically provided a benchmark 
for change after cancer treatment (Mulhern, Merchant, Gajjar, Reddick, & Kun, 
2004). Early reviews reported declines in IQ of up to ten points after CRT treatment 
(e.g. Cousens, Waters, Said, & Stevens, 1988), whilst subsequent reviews revealed 
only mild intellectual declines over time, with most survivors achieving IQ scores 
within the average range (Mulhern et al., 2004; Roman & Sperduto, 1995).  
 
Closer examination of survivors has allowed the identification of vulnerable 
subgroups. Specifically, more substantial deficits have been recognised in groups of 
children treated with CRT at a younger age, and with higher doses (Grill et al., 1999; 
Kieffer‐Renaux et al., 2000; Silber et al., 1992). Dose-response relationships are 
particularly well-documented between CRT dosage and later intellectual functioning, 
for example, Silber et al. (1992) found that medulloblastoma patients treated with 36 
Gray (Gy) CRT scored 8.2 IQ points below those treated with 24Gy, who scored 
12.3 points below those who received 18Gy. Although there is some evidence that 
survivors treated with low dose CRT show observable neurocognitive deficits (e.g. 
Robinson, Fraley, Pearson, Kuttesch, & Compas, 2013), IQ decline is most 
frequently reported in studies of patients who received doses greater than 24Gy (e.g. 
Mulhern, Fairclough, & Ochs, 1991). Further research has extended these findings to 
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reveal an interaction between CRT dosage and age; in a prospective and randomised 
clinical trial conducted by the Pediatric Oncology Group in the US, survivors who 
were younger at the time of CRT (<8.8 years of age) and treated with a higher dose 
showed a 10-15 point decline in IQ, whereas older children did not demonstrate the 
same deficit (Mulhern et al., 1998). There is ongoing controversy, however, about 
the effect of age on IQ according to the chosen definition of ‘younger age’. Many 
studies have arbitrarily determined cut-offs of between two and 12 years of age to 
compare outcomes across (e.g. Armstrong, Gyato, Awadalla, Lustig, & Tochner, 
2004; Bledsoe, 2016; Moore, Ater, & Copeland, 1992; Mulhern et al., 1998; Palmer 
et al., 2001; Pulsifer et al., 2015), thus it remains largely unclear how survivors 
treated during adolescence are affected.  
 
Decline in IQ is broadly recognised to be secondary to white matter changes in the 
brain, which increase with both higher CRT dosage and younger age at time of 
treatment (Corn et al., 1994; Mulhern et al., 2001; Mulhern et al., 1999; Reddick et 
al., 2000).  All cancer treatment protocols prescribed to children and adolescents are 
constrained by the balance between successful disease control and adverse effects on 
cognition. For CRT, it is proposed that the therapeutic action of ionising radiation 
used to kill malignant cells also affects adjacent healthy cells in the central nervous 
system (CNS), leading to cognitive dysfunction. Proliferating cells such as glial and 
vascular endothelial cells have been identified as especially sensitive to irradiation 
and may be responsible for the white matter changes associated with declining IQ 
(Kudo et al., 2014). However, the hippocampal granule cell layer in the dentate gyrus 
(the major site of adult neurogenesis) has been evidenced in animal models to be 
damaged by CRT at much lower doses than those needed to affect glial or neural 
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brain cells (Monje & Palmer, 2003), therefore it is reasonable to assume that 
hippocampal functions may be impaired at lower doses than those needed to affect 
IQ.  
 
The hippocampus has been shown to have several important roles in memory, 
learning, and spatial processing (Bartsch, 2012), and is also implicated in the 
development of post-traumatic stress disorder (PTSD) as part of the neural basis for 
involuntary memory retrieval (Brewin, Gregory, Lipton, & Burgess, 2010; 
Moscovitch, 1995). Although previous research has suggested CRT-induced 
impairment in most of the diverse range of hippocampal functions, including 
memory and spatial navigation (Armstrong et al., 2000; Pereira Dias et al., 2014), 
few studies have focused on the impact of CRT on involuntary memory retrieval, and 
none to date have examined an adolescent population. Furthermore, given that both 
white matter networks and several hippocampal brain regions show unique 
developmental trajectories during adolescence, it is possible that the impact of CRT 
on hippocampal functions in this age group may differ from both younger children 
and older adults.  
 
Psychosocial functioning 
The focus of late effects research is also starting to broaden to psychological and 
social outcomes, as it has been proposed that cognitive and psychosocial functioning 
may be bi-directionally related. For example, Maddrey et al. (2005) suggested that 
the majority of brain tumour survivors in their study were unable to drive as a result 
of CRT-related visuospatial, motor, and executive impairments, which served to 
further restrict vocational and social opportunities. Moreover, several large cohort 
studies have identified CRT specifically as a risk factor for poorer health-related 
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quality of life, mediated by neurocognitive outcomes, in adult survivors of childhood 
brain tumours (Hudson et al., 2003; Zeltzer et al., 2008; Zeltzer et al., 2009).  
 
Crucially, from the few studies that have investigated the relationship between age at 
treatment and subsequent psychosocial functioning, it seems that different stages of 
development may be associated with specific deficits.  Aarsen et al. (2006) found 
that survivors who received treatment in adolescence reported lower social 
adjustment, based on a health-related quality of life measure, compared with children 
treated at younger ages. Receiving treatment for cancer as an adolescent typically 
results in renewed dependence on parents, and a reduced ability to participate in peer 
activities, which may threaten the accomplishment of the key developmental tasks of 
adolescence. Failure to achieve these tasks could predispose adolescent cancer 
patients to problems with psychosocial functioning that extend into adulthood (Stam, 
Grootenhuis, & Last, 2005). 
 
Similarly, having cancer in adolescence presents many emotional and psychological 
challenges, both during treatment and in the survivorship stage. Physical changes 
caused by cancer treatments (including hair loss and scarring) may substantially 
affect developing body image and sense of identity, and the requirement some 
adolescents face to prematurely confront their own mortality is likely to lead to 
difficulty in integrating their experiences into normal life once treatment has ended. 
Indeed, many adult survivors of adolescent cancers report increased post-traumatic 
stress (Hobbie et al., 2000) and psychological distress (Kazak et al., 2010) compared 
to survivors of childhood cancers.  
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Moreover, the evidence regarding the emotional late effects of CRT is mixed, and 
based on only a small corpus of studies. Whilst some studies have found no 
relationship between CRT and depression (Roman & Sperduto, 1995), others have 
suggested that depression increases with years after treatment and is possibly related 
to fatigue, cognitive impairment, and the need for greater family support (Armstrong, 
Goldstein, Cohen, Jo, & Tallent, 2002).  
 
Additional risk factors 
Besides the previously discussed risk factors of higher CRT dosage, and younger age 
at treatment, a multitude of other factors are proposed to affect neurocognitive and 
psychosocial outcomes in adult survivors of childhood and adolescent cancers. 
Ullrich and Embry (2012) discuss four broad categories of risk factors for 
neurocognitive dysfunction: cancer-related factors (such as cancer type and tumour 
location); survivor-related factors (such as gender, baseline level of functioning, and 
time since treatment); treatment factors (such as surgery, chemotherapy, and CRT 
dosage); and environmental factors (such as school absences and family support). 
 
While the benefits of rigorous study design are universally acknowledged, it is not 
feasible for research in this area to account for all potentially confounding factors, 
even in large trials (Armstrong et al., 2004). The majority of studies evaluating the 
specific effects of CRT in cancer survivors must prioritise key variables according to 
the aims of the study and methodological limitations. Although the present study is 
primarily concerned with the effects of CRT in adolescence, it will also consider the 
impact of three additional risk factors proposed to have significant effects on 
neurocognitive and psychosocial outcomes. Besides age, the two most widely-
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documented risk factors in both the brain tumour and leukaemia literatures are those 
of CRT dosage and concurrent treatments, especially chemotherapy (Duffner, 2004; 
Duffner, 2010; Roman & Sperduto, 1995). Time since completing treatment is also 
highlighted as an important risk factor, particularly for intellectual functioning, as 
longitudinal studies of brain tumour patients have revealed increasing declines in IQ 
over time (Mulhern et al., 2001; Palmer et al., 2003; Ris, Packer, Goldwein, Jones-
Wallace, & Boyett, 2001).  Furthermore, recent work has focused on defining the 
relationships between risk factors as it is recognised that they may not act on 
outcomes independently; for example, several studies propose a multiplicative effect 
of CRT and chemotherapy on brain integrity, even when the CRT dose is relatively 
low (Brown et al., 1992; Correa et al., 2004; Deangelis, Yahalom, Thaler, & Kher, 
1992; Gavrilovic, Hormigo, Yahalom, Deangelis, & Abrey, 2006). 
 
Rationale and aims of the study 
Treatment of adolescents with cancer is challenging, particularly in a healthcare 
system that has historically been dichotomised into paediatric and adult care. Only 
recently have health policy initiatives started to recognise adolescent cancer patients 
as a distinct population with unique needs. In light of guidelines published by the 
National Institute of Health and Clinical Excellence (NICE, 2005), adolescents are 
now mostly treated in dedicated teenage and young adult cancer units with 
specialised multidisciplinary teams and late effects services. However, compared 
with the sizeable body of literature that exists for survivors of childhood cancers, 
there is limited research into late effects of cancer diagnosed in adolescence to 
inform these services. Improved understanding of neurocognitive and psychosocial 
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outcomes is critical in supporting healthcare providers to tailor services for cancer 
survivors according to their specific needs. 
 
Given the paucity of studies investigating the late effects of adolescent cancers, the 
aims of the present study are largely exploratory. In accordance with the 
neurocognitive late effects literature, the present study will investigate the effects of 
CRT on IQ and intrusive imagery (hypothesised to be related to hippocampal 
functioning) in adult survivors of adolescent cancers treated with minimum CRT 
doses of 24Gy. It is hoped that these findings will be enriched by the additional 
consideration of psychosocial late effects, as few studies to date have examined the 
impact of CRT during adolescence across more than one domain of functioning.  
 
Furthermore, although many studies investigating treatment effects have compared 
cancer survivors to healthy controls, this design overlooks the likely psychosocial 
impact of diagnosis and treatment. Consequently, the current study compares adult 
survivors of cancers of the central nervous system (CNS) treated with CRT to a 
control group of solid tumour survivors who experienced many of the same 
treatments (such as chemotherapy and surgery) and acute sequelae of cancer 
treatment (such as absence from school and restricted peer interaction), except they 
received non-CNS radiotherapy to parts of the body other than the cranium.  It is 
hoped that results from this study will provide a preliminary overview of how 
receiving radiotherapy to the brain during adolescence, amongst several other risk 
factors, affects multiple domains of functioning in later life, establishing a precedent 
upon which future research can be built.  
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Research questions 
Primary question: 
1. Do the late effects of receiving radiotherapy to the brain (CRT) in 
adolescence differ from those associated with receiving radiotherapy 
elsewhere in the body across domains of neurocognitive, social, and 
psychological functioning? 
Secondary questions: 
2. How are the same domains of functioning affected by the risk factors of i) 
time since treatment, ii) radiotherapy dosage, and iii) the use of additional 
treatments including chemotherapy and/or surgery)? 
3. How do risk factors interact to affect later functioning? 
 
Method 
 
Participants 
All participants were recruited from a specialist teenage and young adult cancer 
service at a London NHS hospital. Potential participants were identified from a 
database of patients who were diagnosed and treated for cancer between 1999 and 
2016. To be eligible for inclusion, participants must: 1) have received radiotherapy 
within a minimum dosage of 24Gy as part of their cancer treatment, 2) have received 
treatment during adolescence (between 12 and 18 years of age), 3) be aged 18 to 30 
at the time of evaluation, and 4) have completed treatment a minimum of two years 
prior to participation in the study. Exclusion criteria included a history of traumatic 
brain injury, and genetic diagnosis with known association with neurocognitive 
impairment (such as Down’s Syndrome). 
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Of a total of 103 potential participants who met inclusion criteria, 43 (42%) accepted 
to participate. Power calculations revealed that the sample size was adequate to 
detect a medium-to-large effect size assuming two-tailed alpha set to .05.  
 
Twenty-five participants received radiotherapy to the brain and CNS (CRT), and 18 
received non-CNS radiotherapy (RT) elsewhere in the body, depending on the type 
of cancer they were treated for (see Table 1). One participant was excluded from 
analysis due to previous brain injury not disclosed until participation. Within 
survivors treated with CRT, 14 received localised or focal RT specific to the tumour 
site, seven received craniospinal RT with a boost to the primary tumour site, and two 
received craniospinal RT only. Type of RT was not recorded for one participant. All 
controls received non-CNS RT, localised to the site of malignancy.  
 
Table 1.  
 
Types of Cancer within the Sample 
 Frequency Percentage  
Brain cancers n = 25 
 
Medulloblastoma 8 32 
Astrocytoma 4 16 
Germinoma 4 16 
Ependymoma 2 8 
Other 7 28 
Controls n = 18 
 
Hodgkin's lymphoma 8 44 
Ewing's sarcoma 3 17 
Testicular 2 11 
Breast 1 6 
Liposarcoma 1 6 
Osteosarcoma 1 6 
Other 2 11 
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Demographics and additional treatment information are presented in Table 2. 
Alongside RT, 32 participants also received chemotherapy (16 CRT survivors, 16 
controls), and 24 had surgery (16 CRT survivors, 8 controls) as part of their 
treatment protocol. 
 
Procedure 
All eligible participants were sent a letter inviting them to participate in the study, 
together with an information sheet (see Appendix A, B, and C for study 
documentation).  Participants were invited to express interest in the study either 
through the return of a tear-off slip or via email. The letter was followed by a phone 
call approximately two weeks later. All participants were offered a £10 online 
shopping voucher as compensation for their time. Data were collected in a one-off 
session lasting approximately 90 minutes, arranged to coincide with participants’ 
other hospital appointments where possible.  
 
Ethics 
Ethical approval was obtained from the North of Scotland Research Ethics Service 
(Ref: 17/NS/0082, Appendix D) and the Health Research Authority (Appendix E). If 
participants presented with psychological distress during participation in the study, a 
referral to the psychology service at the hospital was discussed with them. A total of 
three participants (two from the CRT group, one from the control group) were 
referred to the psychology service for support with concerns unrelated to 
participation in the study.  
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Measures 
 
Demographic and treatment information 
Data regarding participants’ gender, ethnicity, age at diagnosis and evaluation, 
cancer diagnosis, treatment received (including additional chemotherapy and/or 
surgery), RT dosage, relapse, and time since treatment were extracted from the 
hospital patient information database.  
 
Cognitive Functioning 
The Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II; 
Wechsler, 2011). The WASI-II was used to obtain an estimate of intellectual 
functioning, measured by intelligence quotient (IQ). The WASI-II is widely used in 
research, including in studies of cancer survivors, as it allows estimates of IQ scores 
to be obtained quickly and accurately when a full battery is not feasible. It is 
comprised of four subtests; two assess verbal abilities (Vocabulary, Similarities) and 
two assess performance abilities (Block Design, Matrix Reasoning). The battery was 
standardised using a large and representative US normative sample, aged from 6 to 
90 years old. Scores from each subtest are compared to age-specific population 
norms in order to generate t-scores, which are then summed and converted to three 
standardised scores of verbal comprehension, perceptual reasoning, and full-scale IQ.  
 
For the purposes of the present study, only full-scale IQ (based on all four subtests) 
was examined. This index score has been shown to be internally consistent in both 
child and adult populations, with average reliability coefficients of Cronbach’s α 
=.93 and .94, respectively (McCrimmon & Smith, 2013). Concurrent validity was 
established with the full Wechsler intelligence scales and measures of academic 
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achievement, with correlations ranging from r = .71 to .92 (McCrimmon & Smith, 
2013). 
 
Psychological Functioning 
The Patient Health Questionnaire-9 items (PHQ-9; Kroenke, Spitzer, & 
Williams, 2001). The PHQ-9 was used to assess depressive symptomatology. The 
nine items each represent one of the DSM-IV symptoms criteria for major depression 
(e.g. ‘poor appetite or overeating’) and are scored on a frequency scale from 0 (‘not 
at all’) to 3 (‘nearly every day’) over two weeks.  The PHQ-9 demonstrated good 
reliability (Cronbach’s α =.89) and good construct validity when compared to other 
depression measures in the original primary care population for which it was 
developed (Kroenke et al., 2001) and, more recently, in an adult cancer population 
(Johns et al., 2013). PHQ-9 scores of 10 or more had sensitivity of 88% and 
specificity of 88% for major depression, with scores of 5, 10, 15, and 20 representing 
mild, moderate, moderately severe, and severe depression, respectively (Kroenke et 
al., 2001). 
 
The Generalised Anxiety Disorder Scale-7 items (GAD-7; Spitzer, Kroenke, 
Williams, & Löwe, 2006). The GAD-7 was used to assess anxiety symptomatology. 
The items are scored in the same way as the PHQ-9, on a frequency scale from 0 to 
3. Internal consistency has been shown to be excellent (Cronbach’s α = .92), and 
convergent validity was good, evidenced by strong correlations with other 
established anxiety measures (Spitzer et al., 2006). Scores of 10 or more showed 
sensitivity and specificity of 89% and 82%, respectively, and were therefore used as 
cut-offs in the present study (Spitzer et al., 2006). Scores of 5, 10, and 15 can be 
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interpreted as representing mild, moderate, and severe levels of anxiety, similar to 
depression severity on the PHQ-9. 
 
Intrusive Imagery Interview (Glazer, Mason, King, & Brewin, 2012). An 
Intrusive Imagery Interview was used to assess participants’ experiences of intrusive 
imagery, as intrusive images are prominent in many psychological disorders, 
including under the ‘re-experiencing’ cluster of PTSD symptoms (American 
Psychiatric Association, 2013; Brewin et al., 2010). The version of the structured 
interview used in the present study was developed by Glazer et al. (2012) and used 
within a healthy population, though it was based on an interview developed by Patel 
et al. (2007) for use with depressed patients. Following a brief description of 
intrusive imagery, participants were asked how many intrusive images and/or 
memories they had experienced over the past week, and then up to two were 
explored in further detail. Participants were asked to rate the image on several factors 
on a scale from 0 (‘not at all’) to 100 (‘very much’), including the vividness, the 
extent to which various emotions accompanied the image (sadness, anxiety, 
happiness, anger, helplessness, shame, guilt), and the extent to which various senses 
were engaged (olfactory, taste, auditory, tactile, visual). Participants were also asked 
to rate the sense of ‘nowness’ associated with the image, which was defined as “the 
extent to which it felt like the image was actually happening in the present” (see 
Appendix F). Five scores were generated from participant responses; the total 
number of intrusive images experienced over the past week, the emotional intensity, 
‘nowness’, vividness, and sensory associations of these images. Emotions and 
sensory scores were generated using the highest rating given across the seven 
emotions and five senses items. Where two images were reported, the highest score 
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on each variable was used. Where participants reported at least one image, the nature 
of the images was also classified according to whether they were cancer-related 
(non-related vs at least one cancer-related).  
 
Social Functioning 
The Impact of Cancer for Childhood Cancer Survivors Scale (IOC-CS; 
Zebrack, 2009). The IOC-CS was developed as a measure of the physical, 
psychological, and social impact of long-term survivorship, and was used in the 
present study as a measure of social functioning (see Appendix G). The IOC-CS 
aims to measure distinct constructs relevant to the young adult cancer survivor 
population that other existing standardised measures may not evaluate. Initially 
developed as an 82-item questionnaire from interviews with 64 young adult cancer 
survivors (Zebrack, 2009), the IOC-CS was later validated in a sample of 519 
survivors (Zebrack et al., 2010). Items were refined through factor analysis, revealing 
eight subscales consisting of 45 items; five subscales (Body and Health, Talking with 
Parents, Personal Growth, Health Literacy, Socialising) demonstrate a positive 
impact (e.g. “I like the way my body looks”) and three subscales (Life Challenges, 
Memory and Thinking Problems, Financial Problems) reflect negative impacts (e.g. 
“I have a hard time remembering things from long ago”). Items are scored on a five-
point scale from 1 (‘not at all’) to 5 (‘very much’), and mean scores are calculated for 
each subscale. For these eight subscales, Cronbach’s α ranged from .70 to .86, 
indicating adequate reliability (Zebrack et al., 2010). Items relating to health 
insurance, which are not relevant to a UK population, were excluded. IOC-CS 
subscales were also correlated with other established measures of distress, life 
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satisfaction, and health-related quality of life, indicating good concurrent validity 
(Zebrack et al., 2010).  
 
The IOC-CS also assesses the impact of cancer on siblings and intimate 
relationships, although these items were scaled separately as they were not applicable 
to all respondents. In the present study, only the Sibling subscale was included as the 
majority of participants completed these items (only three participants did not have 
siblings), whereas Relationship Concerns (partnered) and Relationship Concerns 
(non-partnered) were mutually exclusive subscales completed by fewer participants 
each. Furthermore, Cronbach’s α was found to be variable for the relationship 
subscales, but adequate for the sibling subscale (Zebrack et al., 2010). Instead, a 
simple measure of relationship status was determined from responses; participants 
were classified into two groups (single, in a relationship) according to whether they 
completed the Relationship Concerns (non-partnered) subscale or the Relationship 
Concerns (partnered) subscale. 
 
Data preparation 
Each domain of functioning was examined to ensure that variables met assumptions 
of normality using the Kolmogorov-Smirnov test and z-scores calculated for 
skewness and kurtosis. Data were also inspected using box plots and z scores, with 
cases exceeding +/-3 identified as outliers. IQ scores met all assumptions and no 
outliers were identified. Scores on the PHQ-9 and GAD-7 demonstrated mild skew 
which was resolved by square root transformation of both variables. Examination of 
intrusive imagery variables revealed that whilst nowness was normally distributed, 
number of images reported was positively skewed, and vividness, and emotion and 
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sensory scores were negatively skewed. Given that variables would be compared, 
transformations were attempted on all variables but were not successful, therefore 
non-parametric tests were used to examine intrusive imagery variables. Furthermore, 
two outliers identified in number of images reported and one outlier identified 
amongst sensory scores were identified and excluded from analysis. Of the nine 
variables comprising the IOC-CS, four were normally distributed (life challenges, 
body and health, personal growth, health literacy) three showed non-normal 
distributions due to floor effects (memory and thinking, financial problems, sibling) 
and two showed ceiling effects (talking with parents, socialising). Transformations 
were attempted but were not successful on all variables therefore non-parametric 
tests were also employed when exploring IOC-CS variables. 
 
Participant and treatment-related variables were also examined for normality and 
outliers. Time since diagnosis was found to be normally distributed. The distribution 
of RT doses across the sample was significantly skewed, and therefore underwent 
square root transformation. 
 
Statistical analysis 
Data analysis was performed using SPSS, version 24.  
 
Primary question 
In addressing the primary research question, initial descriptive analyses were 
completed to compare IQ scores to population norms, and evaluate depression and 
anxiety scores according to pre-defined cut-offs to calculate the percentage of 
participants who were impaired in terms of cognitive or psychological functioning. 
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CRT and control groups were then compared on all domains and variables using 
independent samples t-tests for continuous data (FSIQ), chi square for categorical 
data (relationship status, type of intrusive image), and MANOVAs where variables 
were considered to measure the same construct (psychological functioning [PHQ-9, 
GAD-7]). Likelihood ratios and exact statistics were used to interpret chi square 
analyses to preserve power in a small sample. Given that several intrusive imagery 
and IOC-CS variables were not normally distributed when examined, non-parametric 
Mann-Whitney tests were used to compare each of the variables in lieu of 
MANOVA, and alpha was set at .025 to reduce the possibility of type I error in the 
context of multiple comparisons. 
 
Secondary questions 
Three risk factors (time since treatment, RT dosage, and the use of additional 
treatments including chemotherapy and surgery) were assessed in addressing the 
second research question. Correlations were completed to examine the relationships 
between RT dosage and time since treatment with all domains of functioning. 
Pearson’s correlations were used, except for variables which were previously found 
to violate assumptions of normality, which were investigated using Spearman’s 
correlations. Additionally, alpha was set at .025 to correct for multiple comparisons. 
Chemotherapy (vs no-chemotherapy) and surgery (vs no-surgery) groups were 
compared using the same approach employed to assess the primary research 
question. 
 
To test the third research question, any significant relationships highlighted in 
planned evaluations of effects of the three risk factors (time since treatment, RT 
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dosage, additional treatment) across domains of cognitive, psychological, and social 
functioning were further explored using hierarchical regression analyses to test the 
effects of risk factors whilst controlling for RT treatment group (CRT vs controls). 
Any identified significant predictors were then entered into additional regression 
analyses to assess any interactions between them. All regression models were 
evaluated with respect to multicollinearity, homoscedasticity, normality, and 
linearity. 
 
Results 
 
Results are presented in three parts, in order of the research questions. First, the 
neurocognitive, psychological, and social late effects observed in adult survivors of 
adolescent cancers treated with CRT are described and compared to those of controls 
(survivors of cancers treated with RT elsewhere in the body). Secondly, the effects of 
three risk factors (time since treatment, RT dosage, additional treatments) are 
presented. Thirdly, the interactions between risk factors evaluated in the second 
section are explored further.  
 
1. Late Effects of CRT across Domains 
 
Descriptive analyses 
Table 2 shows demographic and previous treatment information for all participants, 
and compares those who received CRT and controls (who received RT not to the 
cranium).  There were no significant differences between the CRT group and 
controls except for total radiotherapy dose and the number of participants who 
received concurrent chemotherapy; participants treated with CRT received higher 
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doses of RT than participants who had RT elsewhere in the body and a greater 
proportion of the control group received chemotherapy than the CRT group.  
 
Mean scores and p-values of test scores between participants who received CRT and 
participants who received RT elsewhere in the body can be seen in Table 3.  
 
Cognitive functioning 
IQ. Across CRT and control groups, all participants scored at least within 
the average range compared to population norms. Although participants treated with 
CRT achieved lower IQ scores than controls, this difference was not significant, 
t(40) = 0.68, p = 0.500, r = .11. 
 
Psychological functioning 
Depression and Anxiety. Participants were divided around the recommended 
cut-off point of 10 for moderate depression and anxiety on the PHQ-9 and GAD-7 as 
summarised in Table 3. Six (24%) participants in the CRT group and three (18%) 
controls scored in the moderate range or above for depression. Five (20%) 
participants in the CRT group and three (18%) controls scored in the moderate range 
or above for anxiety. Using MANOVA and Pillai’s trace, there was no significant 
effect of CRT compared to controls on psychological functioning, V = 0.073, F(2, 
39) = 1.54, p = 0.23. 
Intrusive Imagery. Groups also did not differ significantly on intrusive 
imagery variables (total number of images reported, vividness, nowness, and 
emotional and sensory nature of images reported). The type of intrusive images 
reported showed a trend towards being different across groups; participants treated 
101 
 
Table 2.  
Demographic and Treatment Information and Comparison of Groups 
  RT Treatment Group  Concurrent Treatment 
 All 
participants  
(n = 42) 
CRT  
(n = 25) 
Controls  
(n = 17) 
p-
value 
Chemotherapy  
(n = 32) 
No 
Chemotherapy 
(n = 10) 
p-
value 
Surgery 
(n = 24) 
No Surgery 
(n = 18) 
p-
value 
Mean age at diagnosis, years (SD) 
     Range 
14.8 (2.5) 
11-18 
14.2 (2.5) 
11-18 
15.6 (2.5) 
12-18 
0.689 15.1 (2.5) 
11-18 
13.9 (2.4) 
11-18 
0.196 15.3 (2.6) 
11-18 
14.2 (2.4) 
11-17 
0.156 
Mean age at evaluation, years (SD) 
     Range 
22.9 (2.3) 
18-29 
22.3 (2.1) 
18-26 
23.6 (2.4) 
20-29 
0.668 23.1 (2.4) 
20-29 
22.1 (2.1) 
18-25 
0.24 22.9 (2.4) 
18-29 
22.8 (2.2) 
20-27 
0.850 
Mean time off treatment, years (SD) 
     Range 
6.8 (2.6) 
2-14 
6.9 (2.3) 
2-11 
6.7 (3.1) 
2-14 
0.337 6.8 (2.7) 
2-14 
7.1 (2.5) 
2-9 
0.719 6.5 (2.5) 
2-11 
7.3 (2.8) 
4-14 
0.293 
Gender (%) 
     Male 
     Female 
 
30 (71) 
12 (29) 
 
16 (64) 
9 (36) 
 
14 (82) 
3 (18) 
 
0.300 
 
24 (75) 
8 (25) 
 
6 (60) 
4 (40) 
 
0.433 
 
17 (71) 
7 (29) 
 
13 (72) 
5 (28) 
 
0.999 
Ethnicity (%)  
     White 
     Minority 
 
32 (76) 
10 (24) 
 
19 (76) 
6 (24) 
 
13 (76) 
4 (24) 
 
0.999 
 
24 (75) 
8 (25) 
 
8 (80) 
2 (20) 
 
0.742 
 
19 (79) 
5 (21) 
 
13 (72) 
5 (28) 
 
0.720 
Mean dose of radiotherapy, Gy (SD) 
     Range 
47.6 (10.4) 
24-62 
51.7 (7.9) 
24-62 
42.2 (11.1) 
30-59 
0.005 46.2 (11.3) 
24-62 
52.8 (3.3) 
50-59 
0.059 52.7 (4.3) 
41-62 
40.1 (12.3) 
24-60 
0.003 
Chemotherapy (%) 
     Yes 
     No 
 
32 (76) 
10 (24) 
 
16 (64) 
9 (36) 
 
16 (94) 
1 (6) 
 
0.031 
      
Surgery (%) 
     Yes 
     No 
 
24 (60) 
18 (40) 
 
16 (64) 
9 (36) 
 
8 (47) 
9 (53) 
 
0.348 
      
Previous relapse 
     Yes 
     No 
 
6 (14) 
36 (86) 
 
3 (12) 
22 (88) 
 
3 (18) 
14 (82) 
 
0.672 
      
Note: Significant p-values are highlighted in bold text 
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Table 3. 
Mean Scores, p-values, and Effect Sizes for Differences between RT Treatment Groups  
 
N* All 
participants 
Mean (SD) 
% 
impaired 
(N) 
N* CRT 
Mean (SD) 
% 
impaired 
(N) 
N* Controls 
Mean (SD) 
% 
impaired 
(N) 
p-value Effect size 
 
r ηp² 
Intellectual functioning 
     IQ 
 
42 
 
103.7 (11.7) 
 
0ᵃ 
 
25 
 
102.7 (13.2) 
 
0ᵃ 
 
17 
 
105.2 (9.0) 
 
0ᵃ 
 
0.500 
 
0.107 
 
Psychological functioning 
     Depression 
     Anxiety 
 
42 
42 
 
6.6 (4.7) 
5.5 (4.1) 
 
21.4ᵇ (9) 
19.0ᵇ (8) 
 
25 
25 
 
7.36 (5.2) 
5.24 (4.3) 
 
24.0ᵇ (6) 
20.0ᵇ (5) 
 
17 
17 
 
5.47 (3.6) 
5.82 (3.9) 
 
17.6ᵇ (3) 
17.6ᵇ (3) 
0.227 
0.233 
0.675 
 
0.073 
0.004 
0.035 
Intrusive Imagery 
     Total number of images 
     Emotions (max. 100) 
     Vividness (max. 100) 
     Nowness (max. 100) 
     Sensory (max. 100) 
     Type of images reported 
          No images reported           
          Non-cancer related           
          At least one cancer-related 
 
40 
35 
35 
35 
34 
42 
 
18.7 (40.9) 
72.4 (24.7) 
71.8 (23.1) 
47.4 (34.6) 
87.4 (24.7) 
N 
5 
28 
9 
 
 
23 
21 
21 
21 
20 
25 
 
11.8 (12.3) 
77.1 (20.8) 
70.1 (30.8) 
47.6 (37.4) 
87.1 (22.3) 
N 
2 
15 
8 
 
 
17 
14 
14 
14 
17 
17 
 
9.5 (12.6) 
65.4 (29.1) 
74.3 (24.5) 
47.1 (31.3) 
87.7 (14.9) 
N 
3 
13 
1 
 
 
0.394 
0.190 
0.966 
0.940 
0.915 
0.069 
 
-0.137 
-0.224 
-0.001 
-0.014 
-0.020 
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Social functioning 
     Life challenges (-) 
     Body and health (+) 
     Talking with parents (+) 
     Personal growth (+) 
     Memory and thinking (-) 
     Health literacy (+) 
     Socialising (+) 
     Financial problems (-) 
     Siblings (-) 
     Relationship status 
          Single 
          Partner 
 
42 
42 
42 
42 
42 
40 
41 
42 
39 
40 
 
2.20 (0.74) 
3.22 (0.77) 
3.85 (1.14) 
3.43 (0.95) 
2.78 (0.92) 
3.88 (0.69) 
3.86 (0.88) 
1.74 (0.91) 
2.22 (1.04) 
N 
28 
12 
 
 
25 
25 
25 
25 
25 
23 
25 
25 
23 
24 
 
 
2.26 (0.73) 
3.16 (0.82) 
3.86 (1.18) 
3.44 (1.00) 
3.05 (0.92) 
3.80 (0.73) 
3.84 (0.86) 
1.71 (0.82) 
2.34 (1.06) 
N 
20 
4 
 
 
17 
17 
17 
17 
17 
17 
16 
17 
16 
16 
 
2.09 (0.77) 
3.32 (0.75) 
3.82 (1.10) 
3.42 (0.89) 
2.38 (0.77) 
3.99 (0.65) 
3.90 (0.96) 
1.78 (1.05) 
2.03 (1.01) 
N 
8 
8 
 
 
0.427 
0.521 
0.882 
0.746 
0.009 
0.492 
0.836 
0.766 
0.304 
0.037 
 
-0.125 
-0.101 
-0.024 
-0.052 
-0.399 
-0.110 
-0.034 
-0.048 
-0.167 
 
Note: Effect size r is calculated for intellectual functioning, intrusive imagery, and social functioning variables, and partial eta squared is used for psychological functioning 
(+) higher scores indicate positive impact, (-) higher scores indicate negative impact 
*Ns are different due to missing data, non-applicability, and/or excluded cases  
ᵃCompared to population norms 
ᵇUsing cut-off score of 10 points 
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with CRT reported more cancer-related images than controls, although this 
difference was not statistically significant, Lχ2 (1) = 4.13, p = 0.069. 
Social functioning 
IOC-CS scores. There were no differences detected between participants 
who received CRT compared to participants who received RT elsewhere in the body 
for eight of the nine IOC-CS variables, as summarised in Table 2 (all p > 0.025). 
However, participants who received CRT reported greater problems with memory 
and thinking (Mdn = 3.00) than the controls (Mdn = 2.20), U = 112.0, z = -2.59, p = 
0.009. 
 Relationship Status. There was a significant association between RT location 
and relationship status Lχ2 (1) = 5.06, p = 0.037, such that the odds of being single 
were five times higher if participants received CRT rather than RT to the body. 
 
2. Risk Factors 
 
Given that minimal differences were detected between CRT survivors and controls, 
the groups were combined when exploring risk factors independently. 
 
Time since Treatment 
Although greater time since successfully completing treatment appeared to be 
associated with higher scores on the ‘Talking with Parents’ subscale of the IOC-CS, 
this correlation was not significant at the corrected alpha level, rs = .32, p = 0.042. 
Time since treatment was not related to any other measure of psychosocial or 
cognitive functioning (see Table 4; all p > 0.025). 
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Table 4.  
 
Correlations with Time since Treatment and RT Dosage across Domains  
Time 
Since 
Treatment 
RT Dosage 
Intellectual functioning 
     IQ 
 
-.057 
 
-.406** 
Psychological functioning 
     Depression 
     Anxiety 
 
-.064 
.003 
 
.094 
-.235 
Intrusive Imagery 
     Total number of images 
     Emotions (max. 100) 
     Vividness (max. 100) 
     Nowness (max. 100) 
     Sensory (max. 100) 
     Type of images reported 
 
-.187 
.128 
.071 
-.024 
.273 
.139 
 
.097 
.091 
-.077 
.065 
-.023 
.254 
Social functioning 
     Life challenges (-) 
     Body and health (+) 
     Talking with parents (+) 
     Personal growth (+) 
     Memory and thinking (-) 
     Health literacy (+) 
     Socialising (+) 
     Financial problems (-) 
     Siblings (-) 
     Relationship status 
 
.013 
.073 
.315* 
-.100 
-.212 
.128 
.109 
.100 
-.128 
.200 
 
-.093 
.042 
-.037 
-.078 
-.007 
-.010 
-.044 
-.086 
-.099 
***p < 0.01, **p < 0.025, *p < 0.05 
(+) higher scores indicate positive impact, (-) higher scores indicate negative impact 
 
RT Dosage 
Across all participants, the total RT dosage received was significantly correlated with 
IQ, rs = -.41, p = 0.013 such that participants who received greater doses of RT to 
any part of the body achieved lower IQ scores. RT dosage was not significantly 
related to any measure of intrusive imagery, or psychological or social functioning 
(see Table 4; all p > 0.025). 
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Additional Treatments 
Table 5 presents mean scores and p-values of test scores comparing participants who 
received additional chemotherapy (vs no chemotherapy) and participants who 
received surgery (vs no surgery).  
 
Chemotherapy 
Survivors who received chemotherapy did not differ from those who did not receive 
chemotherapy across all the explored domains of functioning (all p > 0.05). 
 
Surgery 
Using MANOVA and Pillai’s trace, there was an overall effect of surgery on 
psychological functioning, V = 0.27, F(2, 39) = 7.24, p = 0.002. However, separate 
univariate analyses revealed surgery only had a significant effect on anxiety, F(1, 40) 
= 6.49, p = 0.015, such that participants who did not have surgery reported greater 
anxiety than those who did. Having surgery did not significantly affect self-reported 
depression, F(1, 40) = 0.51, p = 0.48. There were no other differences between 
surgery and no-surgery groups on measures of cognitive or social functioning (all p > 
0.05).   
 
3. Associations between Risk Factors 
 
After each risk factor was evaluated independently, significant findings were 
explored further using regression analysis. When analysing the risk factors in 
isolation, RT dosage was found to be correlated with IQ, and anxiety was 
significantly different across surgery groups. Accordingly, regression analyses were 
conducted to explore the predictive effects of proposed risk factors on IQ and  
107 
 
Table 5.  
Mean Scores, p-values, and Effect Sizes for Significant Differences between Additional Treatment Groups  
 
N* Chemotherapy 
Mean (SD) 
N* No 
Chemotherapy 
Mean (SD) 
p-
value 
Effect size N* Surgery 
Mean (SD) 
N* No 
Surgery 
Mean (SD) 
p-
value 
Effect size 
 
r ηp² 
  
r ηp² 
Intellectual functioning 
     IQ 
32 102.2 (11.5) 10 108.8 (11.2) 0.117 0.245 
 
24 102.5 (12.9) 18 105.3 (9.9) 0.45 0.12 
 
Psychological functioning 
     Depression 
     Anxiety 
32 
32 
6.63 (4.74) 
5.31 (3.80) 
10 
10 
6.50 (4.93) 
6.00 (5.20) 
0.929 
0.927 
0.787 
 
0.004 
0.001 
0.002 
24 
24 
6.88 (4.59) 
4.25 (3.74) 
18 
18 
6.22 (5.00) 
7.11 (4.11) 
0.002 
0.481 
0.015 
 
0.271 
0.013 
0.140 
Intrusive Imagery 
     Total number of images 
     Emotions (max. 100) 
     Vividness (max. 100) 
     Nowness (max. 100) 
     Sensory (max. 100) 
     Type of images reported 
          No images reported           
          Non-cancer related           
          At least one cancer- 
                 related  
 
 
32 
28 
28 
28 
27 
32 
 
11.4 (12.9) 
73.0 (26.9) 
75.6 (25.3) 
47.5 (34.9) 
88.3 (17.0) 
N 
4 
23 
5 
 
8 
7 
7 
7 
7 
10 
 
8.5 (10.3) 
70.0 (14.1) 
56.4 (35.4) 
47.1 (36.4) 
83.6 (30.0) 
N 
1 
5 
4 
 
0.418 
0.455 
0.115 
0.960 
0.817 
0.178 
 
-0.035 
-0.130 
-0.210 
-0.010 
-0.043 
 
 
23 
21 
21 
21 
21 
24 
 
11.9 (12.6) 
72.6 (25.3) 
69.5 (30.5) 
45.7 (36.2) 
86.0 (24.4) 
N 
2 
15 
7 
 
17 
14 
14 
14 
14 
18 
 
9.4 (12.2) 
72.1 (24.8) 
75.2 (24.8) 
50.0 (33.3) 
83.2 (24.9) 
N 
3 
13 
2 
 
0.409 
0.992 
0.656 
0.695 
0.939 
0.262 
 
-0.133 
-0.001 
-0.078 
-0.069 
-0.015 
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Social functioning 
     Life challenges (-) 
     Body and health (+) 
     Talking with parents (+) 
     Personal growth (+) 
     Memory and thinking (-) 
     Health literacy (+) 
     Socialising (+) 
     Financial problems (-) 
     Siblings (-) 
     Relationship status 
          Single 
          Partner 
 
32 
32 
32 
32 
32 
30 
31 
32 
31 
30 
 
2.06 (0.63) 
3.25 (0.81) 
3.89 (1.04) 
3.44 (0.91) 
2.78 (0.95) 
3.97 (0.71) 
3.87 (0.86) 
1.78 (0.87) 
2.26 (1.13) 
N 
19 
11 
 
10 
10 
10 
10 
10 
10 
10 
10 
8 
10 
 
2.60 (0.96) 
3.14 (0.75) 
3.70 (1.45) 
3.40 (1.12) 
2.78 (0.84) 
3.60 (0.59) 
3.83 (1.01) 
1.60 (1.06) 
2.06 (0.56) 
N 
9 
1 
 
0.091 
0.615 
0.830 
0.901 
0.994 
0.112 
0.982 
0.324 
0.995 
0.139 
 
-0.262 
-0.080 
-0.035 
-0.021 
-0.001 
-0.253 
-0.001 
-0.155 
-0.001 
 
 
24 
24 
24 
24 
24 
23 
23 
24 
23 
24 
 
2.26 (0.85) 
3.29 (0.81) 
3.93 (1.23) 
3.35 (0.99) 
2.89 (0.99) 
4.01 (0.73) 
3.88 (0.95) 
1.63 (0.70) 
2.18 (1.11) 
N 
18 
5 
 
18 
18 
18 
18 
18 
17 
18 
18 
17 
17 
 
2.11 (0.59) 
3.13 (0.77) 
3.74 (1.02) 
3.55 (0.90) 
2.62 (0.81) 
3.71 (0.62) 
3.83 (0.82) 
1.89 (1.14) 
2.26 (0.97) 
N 
10 
7 
 
0.692 
0.508 
0.352 
0.645 
0.483 
0.156 
0.650 
0.777 
0.643 
0.296 
 
-0.063 
-0.104 
-0.145 
-0.072 
-0.110 
-0.226 
-0.073 
-0.045 
-0.076 
 
Note: Effect size r is calculated for intellectual functioning, intrusive imagery, and social functioning variables, and partial eta squared is used for psychological functioning 
(+) higher scores indicate positive impact, (-) higher scores indicate negative impact 
*Ns are different due to missing data, non-applicability, and/or excluded cases  
ᵃCompared to population norms 
ᵇUsing cut-off score of 10 points
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anxiety. Two hierarchical regression analyses were completed for IQ and anxiety, to 
test the effects of risk factors after controlling for RT treatment group (CRT vs 
control). It was necessary to control for RT treatment group because previous 
analysis showed that CRT and control groups differed in terms of RT dosage and use 
of concurrent chemotherapy. RT treatment group (CRT vs controls) was entered at 
step one and RT dosage, chemotherapy, and surgery added simultaneously on a 
second step. Time since treatment was not included as it was found to be comparable 
across CRT and control groups, and no associations with either IQ or anxiety were 
identified. 
 
IQ 
RT treatment group (CRT vs control) did not significantly predict IQ scores at step 
one, R2 = 0.004, F(1, 35) = 0.14, p = 0.709. Introducing the risk factors at step two 
explained a significantly greater proportion of the variance in IQ (ΔR² = 0.220, p = 
0.044), and when all four variables were included in the model, the cumulative 
variance in IQ accounted for was 22.4%. Although the overall model was not 
significant at step two, R2 = 0.224, F(4, 32) = 2.31, p = 0.079, both RT dosage and 
chemotherapy were found to be significant predictors of IQ (see Table 6).  
 
In interpreting this regression analysis and assessing multicollinearity, findings of 
preliminary analyses were considered, which identified differences in RT dosage 
between CRT and control groups, and surgery and no-surgery groups. Although 
correlations between RT dosage, and RT treatment group, r = .45, p = 0.002, and 
surgery group, r = 0.60, p < 0.001 were found, tests of multicollinearity indicated 
that only a low level was present (VIF = 1.33 for RT treatment group, VIF = 1.83 for 
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RT dosage, VIF = 1.56 for surgery, VIF = 1.14 for chemotherapy). Results therefore 
suggest that RT dosage and chemotherapy are independent predictors, the effects of 
which cannot be accounted for by RT treatment group. 
 
Table 6.  
 
Multiple Regression Analysis of Factors Predicting IQ Scores 
   
B SE B ẞ t p 
Step 1 
     
 
Constant  104.81 3.06 
   
 
RT Treatment Group -1.53 1.06 -.06 -0.38 0.709 
Step 2 
     
 
Constant  136.05 11.23 
   
 
RT Treatment Group 0.33 4.33 .01 -0.08 0.941  
RT Dosage -0.53 0.24 -.46 -2.16 0.038  
Chemotherapy -10.18 4.81 -.35 -2.11 0.042  
Surgery 1.32 4.72 .05 0.28 0.782 
Note: R² = .004 for Step 1, ΔR² = .220 for Step 2 (p = 0.044); significant p-values 
highlighted in bold 
 
These findings were further explored with an additional hierarchical regression 
which aimed to clarify whether the identified predictors of RT dosage and 
chemotherapy had additive or multiplicative effects on IQ. RT treatment group (CRT 
vs controls) was entered at step one, with RT dosage and chemotherapy added 
simultaneously on a second step, and a further interaction variable of RT dosage 
multiplied by chemotherapy (RT dosage x chemotherapy) added on a third step (see 
Table 7). RT dosage and chemotherapy variables were centered before multiplying to 
reduce multicollinearity, which was found to be low across the model (VIF = 1.34 for 
RT treatment group, VIF = 3.90 for RT dosage, VIF = 3.27 for chemotherapy, VIF = 
4.47 for RT dosage x chemotherapy). Although RT dosage and chemotherapy 
remained significant independent predictors of IQ, there was no evidence of an 
interaction between the two variables, as shown in Table 7.  
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Table 7. 
Multiple Regression Analysis of Factors and Interactions Predicting IQ Scores 
   
B SE B ẞ t p 
Step 1       
Constant  104.81 3.06     
RT Treatment Group -1.53 1.06 -.06 -0.38 0.709 
Step 2       
Constant  135.1 10.51     
RT Treatment Group 0.33 4.27 .01 0.08 0.938  
RT Dosage -0.49 0.20 -.42 -2.43 0.021  
Chemotherapy -10.19 4.75 -.35 -2.15 0.039 
Step 3       
Constant  167.30 22.11     
RT Treatment Group 0.75 4.17 .03 0.18 0.859  
RT Dosage -0.95 0.34 -.82 -2.78 0.009  
Chemotherapy -20.60 7.84 -.71 -2.63 0.013  
RT Dosage x Chemotherapy 2.09 1.27 .52 1.65 0.110 
Note: R² = .004 for Step 1, ΔR² = 0.218 for Step 2 (p = 0.017), ΔR² = 0.061 for Step 3 (p = 
0.110); significant p-values highlighted in bold 
 
Anxiety 
RT treatment group did not significantly predict anxiety scores at step one, R2 = 
0.037, F(1, 35) = 1.34, p = 0.256, and the model remained non-significant after 
adding risk factors at step two, R2 = 0.112, F(4, 32) = 1.01, p = 0.415. Furthermore, 
none of the risk factors significantly predicted anxiety scores, as shown in Table 8, 
indicating that surgery may not be a significant risk factor in later anxiety when 
considered alongside other risk factors. 
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Table 8. 
 
Multiple Regression Analysis of Factors Predicting Anxiety 
   
B SE B ẞ t p 
Step 1 
     
 
Constant  6.06 0.94 
   
 
CRT or controls -1.44 1.25 -.19 -1.16 .256 
Step 2 
     
 
Constant  3.58 3.76 
   
 
CRT or controls -1.05 1.45 -.14 -0.73 0.474  
RT Dosage 0.06 0.08 .16 0.72 0.478  
Chemotherapy 1.10 1.61 .12 0.68 0.680  
Surgery -2.35 1.58 -.31 -1.48 0.148 
Note: R² = .037 for Step 1, ΔR² = .076 for Step 2 (p = 0.448); significant p-values 
highlighted in bold 
 
 
Discussion 
 
The aim of the current study was to provide a preliminary overview of how receiving 
radiotherapy to the brain during adolescence affects multiple domains of functioning 
in adulthood. The impact of additional, potentially confounding, risk factors and the 
relationships between them were also examined. Key findings are discussed in order 
of the research questions. 
 
Late effects associated with CRT 
In examining the primary research question, which asked how late effects differed 
for survivors treated with CRT (to the brain) and a control group of survivors treated 
with non-CNS RT elsewhere in the body, few differences were found between the 
groups. Overall, results from all survivors were comparable to the normal population; 
all participants were found to have IQs within the normal range, and the proportion 
of participants reporting significant depression or anxiety was within expected limits. 
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Furthermore, responses on a measure of social functioning suggested generally 
positive adjustments to cancer, and minimal ongoing negative experiences. 
Nevertheless, significant differences between the CRT group and controls were 
found in self-reported memory functioning, and relationship status. 
 
Several explanations are considered in reviewing the finding that the majority of 
participants did not demonstrate significant late effects across domains. The current 
study’s failure to identify differences between CRT and control groups may reflect 
the fact that older age at the time of irradiation is protective, such that minimal 
adverse effects are experienced in adulthood. This explanation is consistent with the 
paediatric literature, which posits that younger children (typically younger than seven 
years) are more vulnerable to the damaging effects of CRT (e.g. Mulhern, Hancock, 
Fairclough, & Kun, 1992; Robinson et al., 2013; Roman & Sperduto, 1995). It is also 
supported by studies exploring post-traumatic growth, which suggest that many 
survivors of adolescent cancer are not negatively affected, and in fact, experience 
increased resilience and psychological growth after successfully completing cancer 
treatment (Barakat, Alderfer, & Kazak, 2006; Greup et al., 2018). 
 
However, it is not possible to definitively conclude from this data that CRT in 
adolescence results in minimal neurocognitive or psychosocial impairment, for 
several important reasons. Firstly, the lack of observed intellectual impairment does 
not rule out the possibility that some decline may have already occurred in other 
areas of neurocognitive functioning. Given that CRT is proposed to predominantly 
damage white matter and subcortical structures (Corn et al., 1994; Reddick et al., 
2000; Scantlebury et al., 2016), and IQ tests primarily measure posterior association 
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cortex integrity (Lezak, 2012), the brief measure of intellectual functioning used in 
the present study may not have been sufficiently sensitive to CRT-induced damage. 
Several studies of older children treated with CRT using alternative measures have 
revealed mild to moderate deficits in memory, attention, verbal learning, novel 
problem-solving, and processing speed (e.g. Armstrong et al., 2004; Kiehna, 
Mulhern, Li, Xiong, & Merchant, 2006; Mulhern et al., 2004), even in the presence 
of average IQ (Packer et al., 1989). Secondly, even if no deficits are present in other 
areas, it is possible that decline may occur in the future, in IQ or other neurocognitive 
functions (see discussion of time since treatment in ‘Risk Factors’). Thirdly, this null 
finding may instead represent a problem with statistical power as the relatively small 
sample size limited the ability of the current study to detect smaller effects.  
 
Differences between CRT and control groups 
Despite most measures suggesting normal functioning across both groups, 
participants treated with CRT reported significantly greater problems with memory, 
and were five times more likely than controls to be single.  
 
The first finding is consistent with those of Ellenberg et al. (2009) and Armstrong et 
al. (2010) who found that a similar group of survivors of CNS malignancies within 
the Childhood Cancer Survivor Study, treated with total or partial brain irradiation, 
reported greater impairment on memory factors than non-CNS cancer survivors and 
siblings. On the basis of these researchers’ conclusions, it seems possible that self-
reported memory problems in the CRT group may reflect genuine memory problems 
not present in controls, which were not measured by the current study. However, 
further research examining the association of self-reported cognition with objective 
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performance has mostly failed to find a relationship, and instead suggests that 
subjective perception of cognition represents a separate construct, more closely 
related to psychological distress (Li, Root, Atkinson, & Ahles, 2016; Marino et al., 
2009; Skaali et al., 2011). Although there were no significant differences observed 
between the groups in depression or anxiety, there was a trend for more of the 
intrusive images reported by CRT-treated brain tumour survivors to be cancer-related 
than those reported by survivors of other cancers, which may indicate increased 
distress and/or preoccupation with cancer in this group that remained non-significant 
in the context of small sample size and low statistical power. 
 
Regarding the second finding, previous studies have found that survivors of CNS 
tumours, particularly those treated with CRT, are less likely to marry and/or form 
intimate relationships than other cancer survivors and healthy peers, owing to the 
impact of CRT on cognitive functioning (Frobisher, Lancashire, Winter, Jenkinson, 
& Hawkins, 2007; Koch et al., 2011; Langeveld et al., 2003). Although relationship 
status was significantly different between CRT and controls in the present study, 
indicating a specific effect of CRT above and beyond the experience of having 
cancer during adolescence, there were no differences observed in IQ, suggesting that 
this difference was not mediated by intellectual functioning. It is possible, however, 
that this finding may be explained by deficits in other cognitive functions not 
measured in the present study. 
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Risk factors 
Time since treatment 
Results suggested no significant effects of time since treatment, which ranged from 
two to 14 years across all participants. Regarding neurocognitive outcomes, this 
finding may again point to a protective effect of treatment during adolescence, 
consistent with studies of survivors of childhood cancer which found that IQ declines 
over time were only observed in survivors who were younger when irradiated 
(Hoppe-Hirsch et al., 1990; Mulhern et al., 1992; Mulhern et al., 2001; Ris et al., 
2001). However, the potential effects of time since CRT treatment on cognition may 
also have been masked by the sole use of IQ measures. Longitudinal studies 
measuring multiple neurocognitive abilities suggest that progressive declines in IQ 
may actually be driven by deficits in other neurocognitive processes, such as 
processing speed, attention, and working memory, which precede deficits in 
intelligence (Krull et al., 2013; Schatz, Kramer, Ablin, & Matthay, 2000). 
Furthermore, Harila et al. (2009) found that whilst both irradiated and non-irradiated 
cancer survivors experienced mild declines over the five years following treatment, 
only irradiated survivors showed further decline leading to impairment 20 years after 
diagnosis. It is therefore possible that deficits in IQ were yet to emerge in the present 
sample of CRT survivors, who participated an average of 6.8 years after treatment 
completion.  
 
Additionally, whilst the follow-up interval may have been too early to detect IQ 
impairment in this sample, it may have been too late to detect psychosocial problems. 
Stam and colleagues (2005) measured ‘course of life’ in 353 Dutch young adult 
survivors of childhood cancers, and found that, although some participants achieved 
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fewer overall social and psychosexual milestones than healthy peers, others simply 
achieved them at later ages. Similar patterns have also been observed in educational 
and vocational outcomes (Dieluweit et al., 2011; Koch, Kejs, Engholm, Johansen, & 
Schmiegelow, 2004). It is therefore also possible that participants initially 
experienced a hampered course of life, but had caught up to peers by the point of 
participation.  
 
Chemotherapy 
Although no differences were detected between participants who received 
chemotherapy and those who did not when risk factors were evaluated 
independently, regression analysis performed to assess each risk factor whilst 
controlling for the RT treatment group (CRT vs controls) indicated that receiving 
chemotherapy in addition to any type of RT was significantly predictive of lower IQ 
scores. The simplest interpretation of this finding is that the higher the number of 
treatment modalities received, the greater CNS risk is incurred (Mulhern, Crisco, & 
Kun, 1983), however, additional surgery was not found to affect IQ. It is also 
possible that additional chemotherapy is administered for more extensive or 
aggressive cancers, thus the cancer itself may also have greater adverse effects on IQ 
(Wassenberg, Bromberg, Witkamp, Terhaard, & Taphoorn, 2001).  
 
Another explanation of this finding is that radiotherapy interacts with chemotherapy 
in specific ways that potentiate its toxic effects on brain integrity, exceeding those of 
either radiotherapy or chemotherapy alone. Specifically, CRT is proposed to disrupt 
the blood-brain barrier, increasing the concentration of chemotherapeutic agents in 
the brain (Deangelis et al., 1992; Wen, 2003). Intrathecal chemotherapy especially, 
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which delivers chemotherapy directly into the cerebrospinal fluid surrounding the 
brain and spinal cord, has been implicated in studies of childhood cancer survivors, 
as being consistently neurotoxic when administered adjuvantly with RT (Armstrong 
et al., 2004; Bleyer et al., 1990; Brown et al., 1992; Duffner, 2004; Peterson et al., 
2008). The present results suggest an additive effect of RT and chemotherapy, such 
that subsequent IQ scores are lower if treated with both modalities. Given that all 
participants received RT, it was not possible to test whether RT (of any dosage) and 
chemotherapy have multiplicative effects on IQ. However, regression analysis 
revealed that RT dosage and chemotherapy did not interact in their effects on IQ, 
suggesting that chemotherapy does not have a more adverse impact when combined 
with higher RT doses, and may have similar effects at lower doses.  
 
RT dosage 
Perhaps the most unexpected finding was that RT dosage also significantly predicted 
IQ, independently of where RT was administered in the body. In comparison to the 
relative wealth of studies which identify adverse neurocognitive outcomes in 
survivors of CNS malignancies treated with CRT, research on neurocognitive effects 
of non-CNS RT in other cancers is limited, even within the paediatric literature. 
When studied as a mixed group of non-CNS malignancy survivors, levels of 
neurocognitive impairment have not exceeded that of healthy sibling controls, and 
cognition has therefore been presumed to be unaffected by non-CNS RT (Ellenberg 
et al., 2009). However, examination of specific non-CNS cancer diagnoses and 
treatment protocols reveals a different picture. Specifically, mediastinal RT (to the 
central compartment of the thoracic cavity) administered in the treatment of 
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Hodgkin’s lymphoma is suggested to be related to neurocognitive dysfunction due to 
its effects on cardiovascular health (Krull et al., 2012; Prasad, 2013). 
 
Despite a multitude of studies documenting the existence of neurotoxicity following 
CRT and its effects on white matter, it remains that little is known about the precise 
mechanisms underpinning the development of dysfunction. Classically, two 
hypotheses have been suggested; in the glial hypotheses, oligodendrocytes 
(myelinating cells) are proposed to be especially vulnerable to irradiation, resulting 
in demyelination (Monje & Palmer, 2003). Alternatively, the vascular hypothesis 
states that injury induced by RT leads to vascular ischaemia and infarction, which in 
turn, leads to white matter necrosis (Pereira-Dias et al., 2014). It is possible that the 
cardiac complications induced by mediastinal RT in Hodgkin’s lymphoma affect 
white matter and neurocognitive functioning in turn, consistent with the vascular 
hypothesis. Research with coronary heart disease patients supports this conclusion as 
multifocal white matter lesions have been identified on magnetic resonance imaging 
in this population (Jeerakathil et al., 2004), alongside problems with processing 
speed, memory, attention, and executive functions (Debette et al., 2007). Moreover, 
this association is suggested to be dose-dependent; whilst low doses of RT (15-
30Gy) may result in some damage to coronary circulation, higher doses (40-45Gy) 
have been associated with early latency for fatal ischaemic disease (Hancock, 
Donaldson, & Hoppe, 1993; Mulrooney et al., 2010). 
 
Although the exact mechanisms remain unclear, it is conceivable that individuals 
treated with CRT and individuals treated with non-CNS RT for Hodgkin’s 
lymphoma may experience similar levels of neurotoxicity following RT in a dose-
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dependent manner, as specified by the glial and vascular hypotheses, respectively. 
Given that a large proportion (44%) of the control group in the present study was 
comprised of Hodgkin’s lymphoma survivors, it is unsurprising that an effect of RT 
dosage was identified independently of RT treatment group (CRT vs non-CNS 
controls). This subgroup of control participants may also further explain the apparent 
lack of differences between groups across other domains of functioning.  
 
Implications and future directions 
If it is assumed that the present sample is representative of the existing population of 
adult survivors of adolescent cancers, there are several important theoretical and 
clinical implications.  
 
Although the observed lack of impairment in the current sample does not allow the 
acceptance of the null hypothesis, if it is true that individuals treated during 
adolescence experience minimal adverse late effects in adulthood, this would have 
significant implications for the proposed mechanisms of CRT-induced damage. 
Despite undergoing another period of neural plasticity in adolescence, current 
findings could suggest that the effects of CRT are specific to the changes occurring 
in the brain during childhood. For example, CRT may affect the process of myelin 
synthesis or cause permanent damage to myelinating glial cells that are expected to 
have matured by adolescence (Monje & Palmer, 2003). This hypothesis is supported 
by a longitudinal structural imaging study of medulloblastoma survivors treated with 
CRT which found that survivors who were aged below 12 at the time of irradiation 
showed successive decreases of white matter volume of -1.1% per year, whilst 
survivors who were older than 12 years at the time of irradiation showed white 
matter growth at a comparable rate to healthy controls (Reddick et al., 2000). It is 
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further supported by the relatively few and benign intrusive images reported by the 
majority of participants in the present study, as this may suggest that at least one 
aspect of hippocampal functioning remains unaffected by CRT in adolescence, even 
at higher doses. Consequently, it is possible that the significant changes in the brain 
during this period do not confer increased vulnerability, and adolescence may, in 
fact, constitute a period of relative resilience to the effects of CRT. However, given 
the significant limitations of the current study, this conclusion and the associated 
implications should be interpreted with great caution. Extensive future research is 
required, with a larger sample of young adult survivors of adolescent cancers and a 
more diverse range of measures, to clarify whether adult survivors treated in 
adolescence experience a true protective effect of age, or whether the current results 
are reflective of the study’s limited methodology and/or statistical power. 
 
Secondly, the identified worse effects of higher CRT doses and the greater combined 
impact of CRT and chemotherapy on IQ may have important clinical implications, 
for example, in choosing or developing treatment protocols for this age group. In an 
effort to limit neurocognitive dysfunction associated with CRT, recent research has 
focused on adjusting paediatric treatment protocols by reducing CRT doses and 
increasing chemotherapy (Shah et al., 2007; Thomas et al., 2000). However, rather 
than reduce the likelihood of impairment, the present findings suggest that 
concurrent chemotherapy during adolescence may have an additive effect on later 
IQ, regardless of RT dosage. Prospective and repeated cognitive assessment should 
therefore be included in any future trials combining RT and chemotherapy.  
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Furthermore, both global injury from CRT in brain tumour survivors, and ischaemic 
vascular damage resulting from RT given to Hodgkin’s lymphoma patients have the 
potential to reduce cognitive reserves, placing survivors at risk for accelerated ageing 
or early-onset dementia (Armstrong et al., 2013). Although no participants within the 
present sample showed impairment in IQ (considered as below average), follow up 
studies and longitudinal prospective studies are needed to elucidate the effects of 
irradiation in adolescence across the lifespan. 
 
Limitations 
Although the main limitations of the present study have already been discussed, 
including small sample size leading to potential problems with statistical power, and 
the reliance on IQ as a sole measure of neurocognitive functioning, there are several 
additional limitations that must be considered.  For example, the heterogeneous 
group of CRT survivors may not all have received equal doses of CRT to the 
hippocampal region, serving to confound the effects of CRT on intrusive imagery. 
Participants also received different regimens of RT, for example, some were treated 
with additional boosts to the primary tumour site, which may also have differing 
effects on later functioning. Future research aiming to assess hippocampal 
functioning in this population could address these limitations by examining the 
associations between similar variables and exact hippocampal volume using 
volumetric analysis. 
 
Furthermore, the use of unstandardised measures such as the IOC-CS and the 
intrusive imagery interview could be said to limit the validity of present findings. 
However, similar intrusive imagery interviews have been used in other studies 
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examining intrusive cognitions and memories in cancer patients (e.g. Brewin, 
Watson, McCarthy, Hyman, & Dayson, 1998; Whitaker, Brewin, & Watson, 2008), 
and despite being in the early stages of development, the IOC-CS is designed 
specifically for young adult cancer survivors, and may therefore have greater clinical 
utility.   
 
Additionally, although survivors of non-CNS cancers who received RT elsewhere in 
the body were chosen to maximise similarities and provide good control, it is 
possible that the groups did not sufficiently differ on the required factors, as 
evidenced by the findings. The response rate of 43% across groups may also indicate 
that individuals who were experiencing poorer outcomes were less likely to 
participate in the study. 
 
Lastly, an inevitable limitation concerned with using a cross-sectional design is the 
unavailability of baseline data and premorbid IQ scores. Longitudinal studies of 
survivors of childhood cancers propose that, although IQ is not often impaired 
(below average) in adult survivors of childhood cancers, individuals treated with 
CRT may still have experienced significant declines above survivors who did not 
receive CRT (Harila et al., 2009; Krull et al., 2013). To further complicate matters, 
there is also mounting evidence that brain tumour patients suffer some cognitive 
deficits prior to commencement of any cancer treatment due to the effects of the 
tumour itself on the brain, which may further confound the effects of CRT (Duffner 
et al., 1993; Tucha, Smely, Preier, & Lange, 2000; Wassenberg et al., 2001). 
Furthermore, other risk factors including tumour location (Ellenberg, McComb, 
Siegel, & Stowe, 1987), and types of chemotherapy known to have greater effects on 
124 
 
cognition, such as intrathecal methotrexate (Cheung & Krull, 2015), were not 
differentiated in the current study. In sum, larger-scale longitudinal studies are 
needed to provide sufficient statistical power to evaluate the relative contributions of 
many risk factors on later functioning, in addition to accounting for baseline 
problems.  
 
Conclusions 
 
The present study is amongst the first to evaluate the late effects of receiving 
CRT in adolescence across domains of neurocognitive and psychosocial 
functioning. Preliminary findings did not detect any adverse outcomes 
associated with receiving CRT in adolescence, nor was there evidence of 
significant differences between CRT and control groups across several 
domains of functioning, except in self-reported memory functioning and 
relationship status. RT dosage and chemotherapy were identified as significant 
risk factors for lower IQ, even in survivors of adolescent cancers treated with 
non-CNS RT,  though IQ scores remained within the average range. Whilst 
these findings could be understood to mean that there is a protective effect of 
receiving CRT in adolescence, this conclusion may be premature, as it is 
constrained by statistical and methodological limitations. Long-term follow-up 
and prospective studies are therefore essential to clarify and extend current 
findings.  
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Introduction 
The following critical appraisal will first reflect on the theoretical and practical 
challenges encountered during the process of project development. It will then 
discuss the methodological limitations inherent in the current research, and more 
generally in the study of adult survivors of adolescent cancers, before suggesting 
how these may be addressed in future research. Finally, this appraisal will consider 
the null findings of the present study and their implications in the context of post-
traumatic growth. 
 
Project Development 
Choice of topic 
In the first year of clinical psychology training, a multitude of potential projects are 
presented and discussed with students to aid the process of topic selection. One of the 
projects offered in the early stages of development was titled ‘Radiotherapy to the 
hippocampus and the impact on intrusive imagery’. This project aimed to extend the 
revised dual representation theory of post-traumatic stress disorder (PTSD) 
developed by Brewin and colleagues, through its application to a young cancer 
population (Brewin, 2001; Brewin, Dalgleish, & Joseph, 1996; Brewin, Gregory, 
Lipton, & Burgess, 2010).  
 
I was initially attracted to this topic as I felt it combined all three of my long-
standing interests in cognitive neuropsychology, health psychology, and working 
with young people. I was also excited by the idea of advancing a theory, and in 
particular, one that explores how brain function directly relates to psychological 
experience. Furthermore, I felt my experiences prior to starting clinical psychology 
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training of working in a general neuropsychology service and a specialist child 
anxiety clinic were well-suited to this research project. 
 
Initial project 
The rationale and the design of the initial project can be understood through a more 
thorough explanation of the theory it was designed to advance. The revised dual 
representation theory of post-traumatic stress disorder (PTSD) specifies the function 
of the hippocampus in memory encoding and retrieval (Brewin, 2001; Brewin et al., 
2010). It proposes two different types of memory representations encoded during a 
traumatic event; one type of representation is largely supported by the amygdala, the 
insula, and the dorsal visual stream, and encodes sensory and emotional information 
in a form similar to how it was originally experienced (S-reps).The other type is 
reliant on the hippocampus and the ventral visual stream, and abstracts sensory 
information, along with the spatial and personal context, to provide a coherent 
narrative to an event (C-reps). In healthy memory, S-reps are retrieved when the 
associated C-rep is voluntarily activated.  
 
The theory further states that in the presence of extreme stress and/or trauma, S-reps 
can be strongly encoded and the hippocampus down-regulated. This can lead to later 
involuntary re-activation of S-reps by associative cues without the corresponding C-
reps and contextual information, experienced as flashbacks in PTSD. These highly 
sensory and emotional images, mediated by the amygdala, often lack temporal 
context and are described as having a sense of “nowness” (Brewin, 2001; Ehlers & 
Clark, 2000; Glazer, Mason, King, & Brewin, 2012). 
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Patients who have undergone radiotherapy were considered an ideal population to 
test this theory, and the original aim was to recruit one group of participants who had 
received focal radiotherapy to the hippocampus, and compare them to a control 
group of participants who received radiotherapy elsewhere in the body. According to 
the theory, it was hypothesised that direct damage to the hippocampus would result 
in poorer contextual processing of information and therefore greater “bottom-up” 
activation of images and memories, similar to the experience of PTSD. Participants 
would be compared across a range of measures designed to assess specific 
hippocampal functions, including an intrusive imagery interview and a virtual 
environment task designed to test allocentric representation (an aspect of spatial 
memory which involves holding in mind the locations of environmental features 
relative to each other) (King, Burgess, Hartley, Vargha‐Khadem, & O' Keefe, 2002; 
King, Trinkler, Hartley, Vargha-Khadem, & Burgess, 2004). 
 
Challenges 
Once the project had advanced through the stages of a written proposal, the next step 
was to discuss the project with the team at the adolescent and young adult oncology 
service within the London hospital at which the project would run. It was through 
these meetings that several obstacles were encountered, resulting in the need to re-
design the project. The main issue that the original project posed was in recruitment; 
the radio-oncologists at the hospital advised that, although it was theoretically 
possible to recruit participants who had had radiotherapy to the hippocampal region, 
there would be relatively few patients meeting the inclusion criteria and those that 
did would also have received radiotherapy to other regions, thus it would not be 
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possible to attribute any differences to hippocampal damage specifically. It was 
mainly for this reason that an alternative emphasis for the project was considered. 
 
Given the recognised paucity of studies evaluating the late effects of radiotherapy in 
adolescent cancer patients, and that relationships had been already been established 
between the researchers and the clinical team, it was decided that the project should 
proceed within this population. Furthermore, it seemed that recruitment was likely to 
be difficult if constrained to any one region of the brain specifically, as different 
radiotherapy treatment protocols are prescribed even for the same tumour type 
(Burnet, Thomas, Burton, & Jefferies, 2004). Consequently, it was decided that the 
study would keep a broad focus on cranial radiotherapy, compared to radiotherapy 
elsewhere in the body. Given the preliminary nature of the study, I further chose to 
explore multiple domains of functioning in the hope of providing an overview of the 
late effects of CRT when administered in adolescence. 
 
Methodological and Theoretical Limitations 
The present research represents a complex area of study, that has been investigated 
using many different methodologies. There remains no accepted methodology, 
though several approaches are evaluated in this critical appraisal. 
 
Studying the specific effects of cranial radiotherapy 
Despite a large literature investigating the effects of radiotherapy to the brain dating 
back to the 1980s, there continues to be significant controversy about its damaging 
effects. This controversy is due, in large part, to the numerous confounding factors 
affecting both retrospective and prospective studies of patients receiving cranial 
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radiotherapy (CRT). Although there are clearly both acute and delayed effects of 
CRT on multiple brain structures, the predictability of developing impairment in any 
one area is reduced by the additional confounding factors of: age at irradiation; type, 
volume, and dosage of radiotherapy received; number of fractions total dose is 
administered in; specific region of brain irradiated; degree of ‘scatter’ incurred by the 
method of irradiation; additional treatments such as chemotherapy and/or surgery; 
and the predisposition to neurotoxicity conferred by genetics, the type of cancer, and 
tumour location in the brain. (Armstrong, Gyato, Awadalla, Lustig, & Tochner, 
2004; Duffner, 2004; Duffner, 2010; Mulhern, Hancock, Fairclough, & Kun, 1992; 
Roman & Sperduto, 1995; Ullrich & Embry, 2012). Furthermore, several of these 
risk factors are proposed to interact in their effects on later functioning, making it 
even more difficult to isolate and ‘unpick’ their relative contributions. This 
overwhelming but by no means exhaustive list goes some way to describing the 
complexity of conducting research in this area. It also highlights the difficulty all 
studies face in drawing conclusions about the specific effects of CRT, over and 
above those of other risk factors. In designing the present study, I was acutely aware 
of the difficulty in accounting for the afore-mentioned multitude of risk factors, 
especially in a smaller sample, and therefore chose to focus on two of the most 
widely-documented (CRT dosage and concurrent treatments), and an additional risk 
factor relevant to the study of late effects (time since treatment). 
 
Use of control group 
Historically, studies investigating the effects of CRT have employed three different 
types of control group. The first and the most commonly used control group involves 
comparison to healthy peers. Whilst some studies have made use of unrelated age-
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matched community controls (e.g. Ehrhardt et al., 2018; Scantlebury et al., 2016), the 
differences between these participants and cancer survivors treated with CRT are 
significant and it is problematic to conclude that any observed differences are due to 
CRT alone. Other studies have examined siblings or twins to minimise 
environmental differences (e.g. Armstrong et al., 2010; Gunn et al., 2015; Said, 
Cousens, Waters, & Stevens, 1989), though these studies mostly assume controls to 
be unaffected by their sibling’s cancer experiences, which may be misleading.  
 
Secondly, many studies have also compared cancer patients treated with CRT to 
cancer patients treated with different modalities, for example Taylor et al. (2007) 
compared CRT-treated individuals to those who received surgery, and many studies 
have compared the effects of CRT and chemotherapy (e.g. Jankovic et al., 1994; 
Massimo, Wiley, Bonassi, & Caprino, 2006; Precourt et al., 2002). This method 
often involves the comparison of different types of cancers, for example brain 
tumour survivors are frequently compared to survivors of non-central nervous system 
(CNS) malignancies such as solid-tumours and lymphoma treated with protocols that 
do not affect the brain (Conklin et al., 2012; Lahteenmaki et al., 2001). Although 
these groups ostensibly have more in common in terms of the experience of cancer 
diagnosis and treatment and the corresponding disruption to development, these 
comparisons are also fraught with multiple confounding factors. For example, both 
surgery and chemotherapy are proposed to affect cognitive functioning, 
independently of CRT or cancer diagnosis (e.g. Scheibel, Meyers, & Levin, 1996; 
van Den Bent et al., 2003). 
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Finally, a small number of studies have compared cancer patients treated with CRT 
to a control group of individuals diagnosed with other non-malignant chronic 
diseases such as rheumatoid arthritis, and Crohn’s disease (e.g. García‐Pérez, 
Sierrasesumaga, Narbona‐García, Calvo‐Manuel, & Aguirre‐Ventalló, 1994). This 
design attempts to account for factors associated with being ill, without the additional 
confounds of other cancer treatments. However, in addition to being practically 
difficult to organise owing to the need to engage two different healthcare services, 
chronic diseases such as rheumatoid arthritis have also been associated with 
cognitive impairment (Meade, Manolios, Cumming, Conaghan, & Katz, 2018). 
Furthermore, Meade and colleagues (2018) propose that one of the mechanisms 
responsible for cognitive impairment in rheumatoid arthritis is the use of medications 
such as methotrexate and corticosteroids, which have also been identified as risk 
factors for cognitive dysfunction following cancer treatment (Taphoorn & Klein, 
2004).  
 
Whilst it seems that no optimal control condition exists, we chose to compare adult 
survivors of CNS cancers treated with CRT to age-matched survivors of non-CNS 
cancers in the current study to ensure similar illness experiences. We also attempted 
to minimise confounding factors by comparing the same treatment (radiotherapy) 
across different sites, rather than comparing different treatment modalities. In this 
way, we hoped to observe the specific effects of completing CRT treatment.   
 
Recruiting young adults 
The focus on young adult survivors of adolescent cancers in the present study was 
also accompanied by an inherent set of challenges, namely in recruitment and data 
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collection.  A key obstacle encountered was in establishing contact with potential 
participants. Given that participants received treatment during adolescence, the 
contact details recorded on the hospital patient information database were often 
outdated, or else belonged to their parents. The developmental tasks associated with 
young adulthood, such as going to university and moving out of the family home, 
meant that it was often difficult to contact participants using their parental addresses 
and phone numbers. 
 
Furthermore, once contact was established additional problems arose concerning 
availability and incentive. Many potential participants were attending college or 
working full-time, which limited their availability to participate. Geographic location 
was also a consideration. Consequently, participants were offered a £10 Amazon 
voucher and payment of travel expenses, and efforts were made to provide evening 
and weekend appointments and/or arrange times when patients were due to attend 
other appointments at the hospital. Although these measures taken rectified these 
problems to an extent, data collection was still affected by high DNA rates, limiting 
eventual sample size.  
 
Selecting measures 
Due to the anticipated difficulties with recruitment, measures were selected to 
maximise likelihood of participation. Research has suggested that time burden is a 
factor in participation rates, with greater uptake observed when the burden of 
commitment is reduced (Newington & Metcalfe, 2014). Therefore, although it is 
likely that more reliable data would be collected from longer, more detailed, 
measures, this consideration had to be balanced against participant burden, and it was 
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decided that data should be collected in a single testing session lasting approximately 
90 minutes. Accordingly, in order to fulfil the aims of the study and measure both 
psychosocial and cognitive late effects, many measures had to be selected with 
brevity in mind which, regrettably, imposed several limitations. 
 
Future research may prefer to examine the late effects of CRT across only one 
domain of functioning, to reduce issues of participant burden whilst improving the 
reliability of findings. For example, if a similar study were to focus on 
neurocognitive outcomes, it would be prudent to include measures of memory, 
attention, and processing speed in addition to IQ as these are proposed to be more 
sensitive to the effects of CRT (Armstrong et al., 2004; Butler et al., 2008; Roman & 
Sperduto, 1995). Furthermore, the effects of CRT on hippocampal functioning may 
have been better evaluated by using one of the specialist virtual reality and 
topographical spatial memory tasks, developed as an alternative to broad spectrum 
memory tasks (Burgess, Maguire, Amp, Apos, & Keefe, 2002; Hartley et al., 2007; 
King et al., 2002). 
 
In the present study, an intrusive imagery interview was also administered to 
evaluate the impact of CRT-induced damage to the hippocampus in lieu of traditional 
PTSD measures. Estimates of the prevalence of PTSD in adult survivors of 
childhood or adolescent cancer vary from 0% to 34.8% (Vuotto, Perez, Krull, & 
Brinkman, 2015). This large range is due, in part, to the varied definitions and 
methods of assessment of PTSD. Greater than the limitation that few assessment 
scales have been validated within a cancer survivor population (Bruce, 2006; 
Tedstone & Tarrier, 2003), is the overarching problem of whether the chronic nature 
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of cancer diagnosis and treatment can be regarded as a discrete traumatic event 
necessary for fulfilment of DSM-5 criteria for PTSD (American Psychiatric 
Association, 2013). Accordingly, many questionnaire measures of PTSD, such as the 
Impact of Events Scale (IES; Horowitz, Wilner, & Alvarez, 1979), ask respondents 
to evaluate their current distress related to a specific event. Although some studies 
have proceeded to use such measures by asking participants to consider their 
experiences of cancer broadly, this may reduce the validity of the instrument in 
detecting PTSD. By using an intrusive imagery interview where participants could 
report any recent naturally-occurring image, the present study was not constrained by 
the consideration of a specific traumatic event. According to the hypothesis proposed 
by the revised dual representation theory, any intrusive images (not necessarily 
cancer-related) may have the potential to be increasingly vivid, and/or accompanied 
by stronger emotional and sensory associations if the hippocampus has been 
damaged by CRT. 
 
In terms of social functioning, the IOC-CS was chosen for inclusion within this 
project to optimise validity, as it purports to measure aspects of long-term 
survivorship specific to this population; for example, items ask about the impact of 
having cancer on fertility, body image, thoughts about dying, relationships, and life 
goals. However, the IOC-CS remains a relatively new measure and therefore, does 
not yet have established norms (Zebrack, 2009; Zebrack et al., 2010). Many 
alternative instruments exist that measure social functioning and/or quality of life 
with established norms, for example, the Pediatric Quality of Life Inventory (PedsQl) 
is perhaps the most widely used quality of life measure containing a cancer module 
(Varni, Seid, & Rode, 1999), and the MOS 36-item Short-Form Health Survey (SF-
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36) is useful as a broad measure of health status with regard to social and 
psychological functioning (Ware & Sherbourne, 1992). However, these measures are 
limited by their ability to generalise to such a specific population of adult survivors 
of childhood and adolescent cancers. Future research choosing to focus on the social 
late effects of CRT with this population should weigh up these advantages and 
disadvantages so as to select appropriate measures with adequate reliability and 
validity.  
 
The choice to use the PHQ-9 and GAD-7 to assess symptoms of depression and 
anxiety, respectively, was primarily due to the speed and ease of completion 
demonstrated by their use as monitoring tools within IAPT services. Other 
questionnaire measures may also have been appropriate to assess psychological 
functioning, such as the Hospital Anxiety and Depression Scale (HADS), which aims 
to assess psychological symptomology independently of common physical symptoms 
that may be associated with medical conditions such as fatigue or insomnia 
(Zigmond & Snaith, 1983). 
 
Post-traumatic Growth 
From my subjective experiences of meeting with young adult cancer survivors and 
discussing their experiences of diagnosis, treatment, recovery, and survivorship, my 
overall impression was one of resilience and positivity. As the project progressed, 
and I became increasingly inspired by the attitudes and adaptive skills of this 
population, I began to consider the concept of ‘post-traumatic growth’. Although not 
formally measured through qualitative or quantitative means in the present study, it 
seemed to me that the majority of participants had positively integrated their cancer 
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experiences with their sense of identity and ambitions. For example, one participant 
reported that having cancer had prompted him to become a healthcare professional, 
and another participant had even published a book about his experiences. 
Subsequently, the findings of the present study, specifically, that neither survivors 
treated with CRT or those treated with radiotherapy elsewhere in the body 
experienced any significant degree of impairment across the multiple domains 
evaluated, prompted me to consider the concept of post-traumatic growth in more 
depth. 
 
Post-traumatic growth (PTG), as originally conceptualised by Tedeschi and Calhoun 
(1995), refers to the positive changes resulting from the struggle through a life-
altering experience. A growing literature exists exploring the PTG processes amongst 
survivors of childhood and adolescent cancers, which suggests that a significant 
proportion of cancer survivors experience a degree of positive adaptation (Husson et 
al., 2017). Age at the time of cancer diagnosis is also proposed to be related to PTG, 
such that older children and adolescents report greater PTG during survivorship 
(Barakat, Alderfer, & Kazak, 2006). This may suggest that participants in the current 
study did not report impairment due to increased PTG.  However, there is ongoing 
debate regarding the relationship between PTG and adverse outcomes. Specifically, 
the association between PTG and post-traumatic stress (PTS) has been well-
described in a review by Meyerson and colleagues (2011); whilst some studies have 
claimed that PTG may buffer the effects of PTS, the majority have conversely found 
that PTG and PTS are positively related (e.g. Frazier, Tashiro, Berman, Steger, & 
Long, 2004), indicating that cancer survivors may experience high levels of both 
(e.g. Barakat et al., 2006; Kilmer & Gil-Rivas, 2010). Further studies of adult 
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survivors of adolescent cancers treated with CRT could explore PTG formally as this 
knowledge may have important clinical implications for the specialist late effects 
services designed for this population. 
 
Conclusions 
It is important to recognise the many complexities and challenges inherent in the 
study of the late effects of CRT and in conducting research with a young adult cancer 
survivor population. Despite careful consideration of these factors within the present 
study, even leading to a re-design in the initial stages, there remain significant 
methodological and theoretical limitations which constrain the subsequent 
conclusions. Nevertheless, the current findings have merit in establishing a basis 
upon which future research into the late effects of receiving CRT in adolescence can 
build. Although research on life-altering events has typically focused on the negative 
sequalae of these experiences, it is further hoped that future studies can integrate 
indices of post-traumatic growth alongside the measurement of adverse 
neurocognitive and/or psychosocial outcomes. 
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